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Summary (150 words) 38 
SARS-CoV-2 neutralizing antibodies (NAbs) protect against COVID-19. A concern regarding SARS-CoV-2 39 
antibodies is whether they mediate disease enhancement. Here, we isolated NAbs against the receptor-binding 40 
domain (RBD) and the N-terminal domain (NTD) of SARS-CoV-2 spike from individuals with acute or 41 
convalescent SARS-CoV-2 or a history of SARS-CoV infection. Cryo-electron microscopy of RBD and NTD 42 
antibodies demonstrated function-specific modes of binding. Select RBD NAbs also demonstrated Fc receptor-γ 43 
(FcγR)-mediated enhancement of virus infection in vitro, while five non-neutralizing NTD antibodies mediated 44 
FcγR-independent in vitro infection enhancement. However, both types of infection-enhancing antibodies protected 45 
from SARS-CoV-2 replication in monkeys and mice. Three of 46 monkeys infused with enhancing antibodies had 46 
higher lung inflammation scores compared to controls. One monkey had alveolar edema and elevated 47 
bronchoalveolar lavage inflammatory cytokines. Thus, while in vitro antibody-enhanced infection does not 48 
necessarily herald enhanced infection in vivo, increased lung inflammation can rarely occur in SAR -CoV-2 49 
antibody-infused macaques. 50 
 51 
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The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic with over57 
157 million cases and 3 million deaths (https://coronavirus.jhu.edu). While the ultimate solution to control the 58 
COVID-19 pandemic is a safe and effective vaccine, neutralizing Ab (NAb) prophylaxis or treatment of in ection 59 
may help to control the pandemic (Graham, 2020; Sempowski et al., 2020). Prophylactic or therapeutic use of 60 
SARS-CoV-2 NAbs in non-human primates (Baum et al., 2020a; Jones et al., 2020; Zost et al., 2020a) or rodent 61 
models (Hassan et al., 2020; Rogers et al., 2020; Wu et al., 2020) have protected against SARS-CoV-2 infection. 62 
Potent SARS-CoV-2 NAbs reported to date predominantly target the RBD region (Baum et al., 2020b; Brouwer et 63 
al., 2020; Cao et al., 2020; Hansen et al., 2020; Ju et al., 2020; Liu et al., 2020a; Pinto et al., 2020; Robbiani et al., 64 
2020; Rogers et al., 2020; Shi et al., 2020; Wrapp et al., 2020a; Wu et al., 2020). In contrast, neutralizing SARS-65 
CoV-2 NTD antibodies (Abs) exhibit more modest neutralization potency (Brouwer et al., 2020; Chi et al., 2020; 66 
Wec et al., 2020; Zost et al., 2020a; Zost et al., 2020b).  67 
A safety concern for clinical use of antibodies is antibody-dependent enhancement (ADE) of infection. ADE 68 
in vitro has been reported for respiratory syncytial virus vaccination, dengue virus vaccination, or dengue virus 69 
infection (Arvin et al., 2020). ADE is often mediated by Fc receptors for IgG (FcγRs), complement receptors (CRs) 70 
or both, and is most commonly observed in monocytes/macrophages and B cells (Iwasaki and Yang, 2020; Ubol71 
and Halstead, 2010). In vitro studies have demonstrated FcγR-mediated ADE of SARS-CoV infection of ACE2-72 
negative cells (Jaume et al., 2011; Kam et al., 2007; Wan et al., 2020; Wang et al., 2014; Yilla et al., 2005; Yip et 73 
al., 2016; Yip et al., 2014).  Additional research has demonstrated FcγR-independent infection enhancement of 74 
SARS-CoV in Vero cells, and isolated an Ab that may h ve enhanced lung viral load and pathology in vivo (Wang 75 
et al., 2016). The ability of SARS-CoV-2 S Abs to mediate infection enhancement i  vivo is unknown, but is a 76 
theoretical concern for COVID-19 vaccine development (Arvin et al., 2020; Bournazos et al., 2020; Haynes et al., 77 
2020; Iwasaki and Yang, 2020).  78 
Here, we identified potent in vitro neutralizing RBD and NTD Abs as well as in vitro infection-enhancing 79 
RBD and NTD Abs from individuals infected with SARS-CoV or SARS-CoV-2. Negative stain electron 80 
microscopy (NSEM) and cryo-electron microscopy (cryo-EM) revealed distinct binding patterns and the precise 81 
epitopes of infection-enhancing and neutralizing Abs. In vitro studies demonstrated that select RBD Abs mediated 82 









However, using monkey and mouse models of SARS-CoV-2 infection, none of the in vitro infection-enhancing 84 
Abs enhanced SARS-CoV-2 virus replication or infectious virus in the lung in vivo. Three of 46 monkeys had lung 85 
pathology or bronchoalveolar lavage (BAL) cytokine levels greater than controls. However, repeat studies with 86 
dose ranges of in vitro enhancing Abs did not increase lung pathology. Thus, in vitro infection-enhancing RBD and 87 
NTD Abs controlled virus in vivo and was rarely associated with enhanced lung pathology. 88 
 89 
RESULTS 90 
Isolation of neutralizing and infection-enhancing SARS-CoV-2 Abs 91 
SARS-CoV-2-reactive monoclonal Abs from plasmablasts or SARS-CoV-2-reactive memory B cells were 92 
isolated (Liao et al., 2009; Liao et al., 2013) from a SARS-CoV-2 infected individual 11, 15 and 36 days post-onset 93 
of symptoms. To identify neutralizing Abs against bo h SARS-CoV and SARS-CoV-2, SARS-CoV-2 S-reactive B 94 
cells were isolated from an individual infected with SARS-CoV ~17 years prior to sample collection (Figures 1A-95 
B, S1A-D). From 1,737 total B cells, we isolated 463 Abs that bound to SARS-CoV-2 S or nucleocapsid proteins in 96 
high-throughput binding screens (Figure 1C; Table S1). We selected 187 Abs using high binding magnitude, 97 
cross-reactivity with human CoVs, high somatic mutation frequency, and long HCDR3 as selection criteria. 98 
Downselected Abs were examined for neutralization of SARS-CoV-2 pseudovirus and replication-competent 99 
SARS-CoV-2. Forty-four of 81 RBD Abs exhibited neutralization of SARS-CoV-2 pseudovirus or replication-100 
competent virus (Figures S1E-J; Tables S2). Ten of forty-one NTD Abs neutralized SARS-CoV-2 in the 101 
293T/ACE2 pseudovirus and plaque reduction assays, at an IC50 as low as 39 ng/mL (Figures S1K-M; Tables S2). 102 
In addition, 5 non-neutralizing NTD Abs enhanced SARS-CoV-2 pseudovirus infection in 293T/ACE2 and 103 
replication-competent SARS-CoV-2 nano-luciferase virus nfection of Vero cells (Figure 1D,E) (Huo et al., 2020) . 104 
NTD Ab infection enhancement was dependent on ACE2 expression. Both ACE2-expressing 293T cells used for 105 
pseudovirus assays and Vero cells lack FcγR expression (Takada et al., 2007). Thus, NTD enhancement of SARS-106 
CoV-2 infection was FcγR-independent. 107 
To assess FcγR-dependent infection enhancement, 100 S-reactive IgG1 Abs were tested for their ability to 108 
facilitate SARS-CoV-2 infection of TZM-bl cells expressing various FcγRs, but lacking ACE2 and TMPRSS2 109 









respectively (Figures 1F-J). The antigen-binding fragments (Fabs) of these Abs did not mediate infection 111 
enhancement of TZM-bl cells expressing FcγRI or FcγRIIb, demonstrating Fc-dependence for enhancement 112 
(Figures 1K-L). Thus, RBD Abs can be either neutralizing in ACE2-expressing 293T cells, infection-enhancing in 113 
the FcγR-expressing TZM-bl cells, or both (Figure 2A). NTD Abs can either be neutralizing or infection-114 
enhancing in the ACE2+ 293T cells or VeroE6 cells (Figure 2A).  115 
 116 
Characterization of infection-enhancing Spike Abs 117 
We compared the phenotypes and binding modes of RBD Abs that either did not enhance or enhanced 118 
infection in order to elucidate differences between them. The selected RBD Abs neutralized SARS-CoV-2 119 
pseudovirus and/or replication-competent virus in ACE2-expressing cells (Figures 2A and S2), despite five of 120 
these Abs mediating infection enhancement in ACE2-negative, FcγR-positive TZM-bl cells (Figures 1F-L, 2A, 121 
and S2). Both types of selected RBD Abs blocked ACE2 binding to S protein and both types of RBD Abs bound to 122 
S with high affinities (range = 0.1 to 9 nM)(Table S3, Figure 2A). Thus, the infection-enhancing or non-enhancing 123 
RBD Abs showed similarities in ACE2 blocking, affinity, and neutralization of ACE2-dependent SARS-CoV-2 124 
infection (Figure 2A).  125 
For six representative RBD Abs, we obtained NSEM reconstructions of Fabs in complex with stabilized S 126 
ectodomain trimer. Infection-enhancing RBD Abs DH104  and DH1043 bound with a vertical approach (Figure 127 
2B), parallel to the central axis of the S trimer, similar to non-infection-enhancing Abs DH1042 and DH1044 128 
(Figure 2C). The epitopes of Abs DH1041, DH1042, and DH1043 overlapped with that of the ACE-2 receptor 129 
(Wec et al., 2020), consistent with their ability to block ACE-2 binding to S protein (Figures 2A and S3A-B). 130 
Their epitopes were similar to those of three previously described Abs, P2B-2F6 (Ju et al., 2020), H11- 4, and 131 
H11-D4 (Figure S3C) (Huo et al., 2020; Zhou et al., 2020a). The epitope f another non-infection-enhancing RBD 132 
Ab DH1044 was only slightly shifted relative to DH1041, DH1042 and DH1043 (Figure 2C), but resulted in 133 
DH1044 not blocking ACE2 binding (Figures 2A and S3A-B). The remaining two RBD Abs, DH1045 and 134 
DH1047, cross-reacted with both SARS-CoV and SARS-CoV-2 S (Figures 2A and S2A-B). DH1047 also reacted 135 
with bat and pangolin CoV spike proteins (Figures 2A and S2A). Although DH1047 mediated FcγR-dependent 136 









angle of approach (Figures 2B-C and S3A) (Pak et al., 2009). Thus, epitopes and binding angles of RBD Abs 138 
determined by NSEM did not discriminate between Absthat mediated FcγR-dependent infection enhancement and 139 
those that did not. 140 
Next we characterized the Fabs of neutralizing NTD Abs DH1050.1 and DH1051 bound to stabilized S 141 
ectodomain with affinities of 16 and 19 nM respectively, whereas the infection-enhancing Ab DH1052 bound with 142 
294 nM affinity (Table S3). NSEM reconstructions obtained for nine NTD Abs showed that the FcγR-independent, 143 
infection-enhancing NTD Abs (DH1053-DH1056) bound to S with their Fab constant domains directed downward 144 
toward the virus membrane (Figure 2D), whereas the five neutralizing NTD-directed Abs (DH1048-DH1051) 145 
bound to S with the constant domain of the Fab directed upward away from the virus membrane (Figure 2E). The 146 
five neutralizing Abs bound the same epitope as Ab 4 8 (Chi et al., 2020), with three of the five having the same 147 
angle of approach and heavy chain gene segment (VH1-24) as 4A8 (Figure S3D-F and Table S2) (Chi et al., 2020). 148 
These NTD Abs may constitute a neutralizing Ab class that can be elicited in multiple individuals. Thus, S protein 149 
Ab epitopes and binding modes were associated with infection-enhancing activity of NTD Abs. 150 
 151 
Competition between infection-enhancing and non-infection enhancing Abs 152 
To determine whether infection-enhancing Abs could compete with non-infection-enhancing Abs for binding 153 
to S ectodomain, we performed surface plasmon resonance (SPR) competitive binding assays. RBD Abs segregated 154 
into two clusters, where Abs within a cluster blocked each other and Abs in different clusters did not bl ck each 155 
other (Figures 3A). One cluster included Abs DH1041, DH1043 and DH1044, and the other cluster included Abs 156 
DH1046 and DH1047. NSEM reconstructions showed combinations of DH1041 and DH1047 Fabs or DH1043 and 157 
DH1047 Fabs bound simultaneously to different epitopes of the stabilized S trimer (Figure 3B).  158 
NTD Abs also segregated into two clusters where one cluster included neutralizing NTD Abs and a second 159 
cluster included non-neutralizing NTD Abs (Figures 3A and 3C). NSEM reconstructions confirmed that the Fabs 160 
of neutralizing NTD Ab DH1050.1 and infection-enhancing NTD Ab DH1052 could simultaneously bind to 161 
distinct epitopes on a single SARS-CoV-2 S trimer (Figure 3D). DH1054 was unique as it was able to block both 162 
infection-enhancing and neutralizing NTD Abs (Figures 3C). 163 
NTD Abs did not compete with RBD Abs for binding to S trimer (Figure 3A), suggesting in a polyclonal 164 








different neutralizing RBD Abs (DH1043 and DH1047) could bind to the same S protomer as neutralizing NTD 166 
Abs DH1050.1 or DH1051 (Figure 3E,F). Thus, in the presence of a polyclonal Ab response, S trimer could be 167 
bound by multiple RBD and NTD neutralizing Ab Fabs. 168 
 169 
FcγR-independent infection-enhancement in the presence of neutralizing Abs 170 
Structural determination of Ab binding modes demonstrated that certain infection-enhancing Abs and non-171 
infection enhancing Abs bound to distinct epitopes on the same S protomer (Figures 3A-F). Infection-enhancing 172 
Ab DH1052 and neutralizing RBD Ab DH1041 were isolated from the same individual. We hypothesized that 173 
infection outcome would be dependent on which Ab was present at the highest concentration. When DH1041 174 
neutralization was assessed in the presence of 1,325-fold excess of Ab DH1052, infection enhancement was175 
observed when DH1041 concentration was below 10 ng/mL (Figures 3G and S4A-C). A nearly identical result 176 
was obtained when we examined neutralization by DH1043 (Figures 3H and S4A-C). In 21 SARS-CoV-2-infected 177 
humans, RBD and NTD serum IgG titers were comparable (Figures S4D-E). Moreover, the prevalence of DH1052 178 
versus DH1041 Abs was assessed using blocking assays and found to be only modestly higher for DH1052 (Figure 179 
S4F). Thus, a ~1000-fold excess of infection-enhancing NTD Ab was required to out-compete the effect of a180 
potent RBD neutralizing Ab in vitro, but such excess amounts of DH1052 was not observed during natural 181 
infection (Figures 3G-H and S4D-F).  182 
 183 
Cryo-EM structural determination of RBD and NTD-directed Ab epitopes 184 
To visualize atomic level details of their interactions with the S protein, cryo-EM was used for structural 185 
determination of selected representative Abs from the panels of RBD and NTD-directed Abs. For all three RBD-186 
directed Abs, the cryo-EM datasets revealed heterogeneous populations of S ectodomain “2P” (S-2P) (Wrapp et al., 187 
2020b) with at least one RBD in the “up” position (Figure 4 and Data S1). We did not find any unliganded S or 188 
any 3-RBD-down S population, although unliganded S-2P consistently shows a 1:1 ratio of 1-RBD-up and 3-RBD-189 
down populations (Henderson et al., 2020; Walls et al., 2020). All S-2P trimers were stoichiometrically bound to 190 
three Fabs, with Abs bound to both up and down RBDs in an S-2P trimer.  191 
We observed that the primary epitopes of DH1041 and DH1043 were centered on the Receptor Binding Motif 192 









blocking phenotype of these Abs. While DH1041 utilized its heavy chain complementarity determining regions 194 
(CDRs) to contact the RBM, the DH1043 paratope included both its heavy and light chains. In contrast, the epitope 195 
of Ab DH1047 was focused around the α2 and α3 helices and ß2 strand that are located outside the N-terminus of 196 
the RBM (Figure 4C and Data S1). DH1047 also contacted RBD residues 500-506 outside the RBM, and stacked 197 
against the N-terminal end of the α3 helix. The DH1047 paratope included heavy chain HCDR2, HCDR3 and light 198 
chain LCDR1 and LCDR3. The HCDR3 stacks against and interacts with the residues in the ß2 strand. Interac ions 199 
with the ß2 strand are also mediated by HCDR2. Similar to DH1041 and DH1043, the DH1047 interacted with an 200 
“up” RBD conformation from an adjacent protomer although these interactions were not well-characterized due to 201 
disorder in that region. 202 
We next determined cryo-EM structures of the NTD-directed neutralizing Abs, DH1050.1 (Figure 4D) and NTD-203 
directed infection-enhancing Ab, DH1052 (Figure 4E), at 3.4 Å and 3.0 Å resolutions, respectively. The cryo-EM 204 
datasets of DH1050.1- and DH1052-bound complexes showed Fab bound to both 3-RBD-down and 1-RBD-up S-205 
2P spikes (Data S1). Consistent with the NSEM reconstructions, the neutralizing Ab DH1050.1 and the non-206 
neutralizing, infection-enhancing Ab DH1052 bound opp site faces of the NTD, with the epitope for the 207 
neutralizing Ab DH1050.1 facing the host cell membrane and the epitope for the non-neutralizing, infection-208 
enhancing Ab DH1052 facing the viral membrane. The dominant contribution to the DH1050.1 epitope came from 209 
NTD loop region 140-158 that stacks against the Ab HCDR3 and extends farther into a cleft formed at the interface 210 
of the DH1050.1 HCDR1, HCDR2 and HCDR3 loops. The previously described NTD Ab 4A8 interacts with the 211 
same epitope in a similar manner as DH1050.1, with its elongated HCDR3 dominating interactions. Although, 212 
DH1050.1 and 4A8 (Chi et al., 2020) show a rotation relative to each other about the stacked HCDR3 and NTD 213 
140-158 loops. The light chains of DH1050.1 and 4A8 do not contact the S protein, which is consistent with their 214 
diverse light chain gene origins (Figure 4E and Data S1). The infection enhancing NTD-directed Ab DH1052 215 
bound the NTD at an epitope facing the viral membrane nd composed of residues spanning 27-32, 59-62 and 11-216 
218, with all the CDR loops of both heavy and light c ains involved in contacts with the NTD. We also observed 217 
contact of the Ab with the glycan at position 603, as well as the conformationally invariant SD2 region. Thus, we 218 
found that the RBD-directed antibodies isolated in th s study influenced RBD dynamics and bound only to spike 219 









conformations. In contrast, the NTD-directed antibod es bound to both the 3-RBD-down and 1-RBD-up spikes that 221 
are present in the unliganded S-2P.  222 
 223 
Effect of in vitro infection-enhancing and neutralizing NTD Abs in mouse and macaque models  224 
Next, we assessed the effect of NTD infection-enhancing Ab DH1052 in a COVID-19 disease mouse model 225 
where aged BALB/c mice were challenged with the mouse-adapted SARS-CoV-2 MA10 strain (Leist et al., 2020a). 226 
DH1052 lacked neutralization of SARS-CoV-2 MA10 (Figure S4G-H). DH1052 or a control influenza Ab CH65 227 
was given 12 hours prior to SARS-CoV-2 MA10 infection (Figure 5A). Throughout the four days of infection, 228 
DH1052-infused mice exhibited similar levels of body weight loss and higher survival than mice given CH65 229 
(Figures 5B-C). In addition, DH1052-treated mice exhibited lower lung hemorrhagic scores, lower lung viral 230 
plaque-forming unit (PFU) titers and lower lung tissue subgenomic RNA (sgRNA) levels compared to control mice 231 
(Figures 5D-F). Therefore, DH1052 treatment resulted in less severe disease and reduced viral replication. FcR-232 
mediated effector functions may have been the mechanism of suppression since DH1052 bound to mouse FcγRI 233 
and FcγRIV (Table S4).  234 
We next examined the effect of infusion of NTD infection-enhancing Ab DH1052, NTD neutralizing Ab 235 
DH1050.1, or control Ab CH65 on SARS-CoV-2 infection in monkeys (Leist et al., 2020b; Rockx et al., 2020). 236 
Cynomolgus macaques were infused with 10 mg of Ab per kg body weight and three days later challenged 237 
intranasally and intratracheally with 105 PFU of SARS-CoV-2 (Figure 5G) (54). Human Ab infusion resulted in 238 
circulating concentrations ranging from 11 to 238 µg/mL in serum at day 2 post-challenge (Figures 5H-I). Sera 239 
with DH1050.1 neutralized SARS-CoV-2 pseudovirus and replication-competent virus, while serum containing 240 
DH1052 or CH65 did not neutralize (Figures 5J-K). Four of 5 macaques that received DH1052 had comparable 241 
lung inflammation to control CH65-infused macaques four days after infection (Figures 5L and S5A). However, 242 
one macaque (BB536A) administered DH1052 showed increased perivascular mononuclear inflammation, 243 
perivascular and alveolar edema (Figure S5B), and multiple upregulated BAL cytokines (Table S5). 244 
Immunohistologic analysis demonstrated alveolar and perivascular infiltration of M2-type macrophages in both 245 
monkey BB536A and a control monkey BB785E (Figures S5C-E). In contrast, macaques administered DH1050.1, 246 









(Figures S5C-E). Infusion of either DH1050.1 or DH1052 reduced viral nucleocapsid antigen (Figures 5M and 248 
S5A), Envelope (E) gene sgRNA and nucleocapsid (N) gene sgRNA in the BAL (Figures 5N-O). In nasal swab 249 
fluid, DH1050.1 and DH1052 reduced E and N gene sgRNA in macaques with the reduction being significant 250 
when neutralizing Ab DH1050.1 was infused (Figures 5P-Q).  251 
Since DH1052-mediated in vitro infection-enhancement increased as the Ab concentration increased (Figures 252 
1D-E), we infused an additional 6 cynomolgus macaques with either 30 mg/kg of DH1052 or CH65 control Ab 253 
(Figure S6A). DH1052 infusion suppressed BAL viral load (Figures S6B-D), significantly reduced virus 254 
replication in nasal swab samples (Figures S6E-G), and showed no enhanced immunopathology or cytokine 255 
secretion (Figures S6H-K, Table S5). Thus, with high dose (30mg/kg) of DH1052 Ab, there was no infection 256 
enhancement. These results suggested that the lung pathology seen in monkey BB536A was rare and may not have 257 
been caused by Ab infusion. 258 
 259 
FcγR-dependent, in vitro infection-enhancing RBD Abs do not enhance SARS-CoV-2 infection in mice 260 
Next, we used a SARS-CoV-2 acquisition mouse model to investigate the in vivo relevance of RBD 261 
neutralizing Abs that also mediated in vitro infection-enhancement (Figures 6A-B). Aged BALB/c mice were 262 
injected intraperitoneally with 300 µg of Ab, and challenged with a SARS-CoV-2 mouse-adapted 2AA MA isolate 263 
12 hours later (Dinnon et al., 2020). Mice received either in vitro infection-enhancing Ab DH1041, non-infection 264 
enhancing Ab DH1050.1, or a combination of both Abs. Administration of DH1041 alone or in combination with 265 
DH1050.1 protected all mice from detectable infectious virus in the lungs 48h after challenge (Figure 6A). In the 266 
setting of therapeutic treatment, administration of DH1041 alone or in combination with DH1050.1 12 hours after 267 
SARS-CoV-2 challenge significantly reduced lung infectious virus titers (Figure 6B). Thus, while RBD Ab 268 
DH1041 could mediate FcγR-dependent, in vitro infection enhancement, it protected mice from SARS-CoV-2 269 
infection when administered prophylactically or therapeutically. 270 
DH1046 and DH1047 are RBD Abs that cross-neutralize SARS-CoV, SARS-CoV-2 and bat WIV1-CoV 271 
(Figures 2A, S2A-B, S2I-L and 6C-E). Both RBD Abs mediated FcγR-dependent, in vitro SARS-CoV-2 infection 272 
enhancement (Figures 1F-L). We assessed the ability of either DH1046 or DH1047 to enhance or protect against 273 









before challenge had no detectable infectious virus in the lung, whereas control IgG administered mice had a mean 275 
titer of 84,896 PFU per lung lobe (Figure 6F). Administration of DH1047 after challenge eliminated detectable 276 
infectious virus in the lung in 3 of 5 mice (Figure 6G). Therapeutic administration of DH1046 reduced infectious 277 
virus titers 10-fold compared to negative control IgG (Figure 6G). Thus, DH1046 and DH1047 did not enhance 278 
infection in vivo, but rather protected mice from SARS-related bat coronavirus infection. 279 
 280 
In vitro infection-enhancing RBD Abs in SARS-CoV-2-challenged nonhuman primates 281 
Finally, we assessed RBD Ab infection-enhancement in cynomolgus macaques (Figures 7A). After Ab 282 
infusion at 10 mg/kg of body weight, serum human IgG concentrations reached 11-228 µg/mL at day 2 post-283 
challenge (Figures 7B-C) and exhibited a wide range of neutralization potenci s against SARS-CoV-2 (Figures 284 
7D-E). Infusion of RBD Ab DH1041, DH1043, or DH1047 resulted in reduced lung inflammation, undetectable 285 
lung viral antigen (Figures 7F-G and S5A), and reduced sgRNA in the upper and lower respiratory tracts (Figures 286 
7H-K). RBD Ab DH1046, a weaker neutralizing Ab compared to DH1041, DH1043 or DH1047 (Figure 2A), did 287 
not enhance sgRNA E or N in BAL or nasal swab samples (Figures 7H-K), but protected only a subset of infused 288 
monkeys. Two DH1046-infused monkeys had increased lung inflammation scores due to increased total areas of 289 
inflammation compared to control Ab monkeys (Figures 7F and S5A), but had no evidence of perivascular or 290 
alveolar edema nor evidence of abnormal BAL cytokines (Table S5). Thus, these two animals had more lung 291 
involved with inflammatory macrophage infiltration but did not have pathological evidence of vascular le kage. 292 
Comparing the DH1046 group to the control IgG group, viral nucleocapsid antigen in the lung was reduce 293 
(Figures 7G and S5A). Thus, the weakly neutralizing Ab only partially limited virus replication and lung 294 
inflammation. 295 
In vitro infection enhancement by RBD Abs was dependent on Ab concentration, with lower levels of Ab 296 
showing the highest magnitude of infection enhancement (Figure 1G). Therefore, we performed an additional 297 
passive infusion study with a series of different concentrations of DH1047 (Figure S7A). Cynomolgus macaques 298 
were infused with 5, 1, or 0.1 mg of DH1047 per kg of body weight resulting in a wide range of DH1047 299 
concentrations in serum (Figures S7B-C). However, none of the groups of macaques had enhanced virus 300 









S7D-G), lung inflammation (Figures S7H-I), lung viral antigen (Figures S7J-K), or higher BAL inflammatory 302 
cytokines (Table S5) compared to the control IgG group.  303 
Overall, 45 of 46 spike enhancing Ab-infused monkeys did not show enhanced virus replication in vivo, while 304 
3 of 46 Ab-treated monkeys exhibited enhancement of lung pathology, with 1 of 46 Ab-treated monkeys had 305 
alveolar and perivascular edema and with elevated BAL inflammatory cytokines. In the case of the latter monkey, a 306 
follow-up study with 3 times the initial DH1052 Ab dose did not confirm DH1052 result in enhanced lung 307 
pathology after SARS-CoV-2 challenge. 308 
 309 
DISCUSSION 310 
Here, we assessed infection-enhancement by SARS-CoV-2 Abs and observed two different types of in vitro 311 
infection enhancement. First, RBD Abs mediated classic l ADE that required FcγRs and Ab Fc for virus uptake 312 
(Lee et al., 2020). Previous studies have demonstrated that uptake of MERS-CoV or SARS-CoV has mostly been 313 
mediated by FcγRIIa on the surface of macrophages (Bournazos et al., 2020; Wan et al., 2020; Yip et al., 2016). In 314 
contrast, we identified SARS-CoV-2 RBD Abs utilized FcγRIIb or FcγRI. Second, non-neutralizing NTD Abs 315 
mediated FcγR-independent infection-enhancement in two different FcγR-negative, ACE2-expressing cell types. 316 
The mechanism of FcγR-negative in vitro enhancement remains unclear, but one previous study has reported that 317 
select NTD Abs can enhance S binding to ACE2 (Liu et al., 2020b).  318 
Macrophages and other phagocytes are the target cells that take up MERS-CoV leading to infection-319 
enhancement (Hui et al., 2020; Wan et al., 2020; Zhou et al., 2014). In contrast, neither SARS-CoV nor SARS-320 
CoV-2 productively infect macrophages (Bournazos et al., 2020; Hui et al., 2020; Yip et al., 2016). However, a 321 
recent study demonstrated that alveolar macrophages harboring SARS-CoV-2 RNA produce T cell 322 
chemoattractants leading to T cell IFN-γ production that in turn, stimulates inflammatory cytokine release from 323 
alveolar macrophages (Grant et al., 2021). Why severe lung pathology and inflammatory cytokine production 324 
occurred in only 1 of 46 monkeys is unknown, but may relate to host-specific differences regulating inflammatory 325 
cytokine production (Bastard et al., 2020; Zhang et al., 2020). It is important to note that the one monkey that 326 
developed alveolar and perivascular edema and elevat d BAL inflammatory cytokines could have been caused by 327 
Ab enhancement of disease, or could have been due to unknown factors that caused more severe disease in animal 328 









(30mg/kg) of DH1052 had enhanced pulmonary disease supports the hypothesis that the lung pathology may have 330 
been a severe case of COVID-19 lung disease unrelated to Ab infusion. 331 
Previous studies with vaccine-induced Abs against SAR -CoV have also shown i vitro infection-332 
enhancement, but no in vivo infection enhancement in hamsters (Kam et al., 2007). One explanation for this results 333 
may be that in vitro enhancing Abs may have the ability to suppress SAR-CoV-2 replication in vivo through non-334 
neutralizing FcR-mediated Ab effector functions (Bournazos et al., 2020; Schafer et al., 2021). A recent study in a 335 
SARS-CoV-2 mouse model of acquisition suggested that Fc effector functions contribute to the protective activity 336 
of SARS-CoV-2 neutralizing Abs C104, C002, and C110 (Schafer et al., 2021). Thus, Ab effector functions may 337 
contribute to the outcome in vivo, but not be accounted for in SARS-CoV-2 enhancement or eutralization assays 338 
in vitro. Consistent with previous findings for human IgG (Dekkers et al., 2017), we observed that DH1052 Ab can 339 
bind to select murine FcγRs.  340 
In vivo, SARS-CoV-2 S trimers circulate in the presence of a polyclonal Ab response. We observed bivalent 341 
and trivalent combinations of Fabs from RBD and NTD neutralizing Abs can recognize the same protomer of the S 342 
trimer. We speculate given the direction of the C-termini of the Fabs and molecular modeling that three IgGs 343 
targeting distinct epitopes may be able to interact with the same protomer, if the IgG hinge region is sufficiently 344 
flexible and the RBD is in an optimal up conformation for simultaneous engagement. Simultaneous engagement by 345 
RBD and NTD Abs could improve synergism of neutraliz tion (Zost et al., 2020a), and avidity of the immune 346 
complexes for FcγRs on effector cells (Nagashima et al., 2011; Nagashima et al., 2008; Wang et al., 2017). These 347 
results indicate three epitopes that Ab prophylactics could target on RBD and NTD in order to occupy S trimers 348 
with multiple IgGs.  349 
Limitations of the Study 350 
Although rare enhanced immunopathology was observed in monkeys, it is difficult to predict whether this 351 
phenomenon will occur in the setting of human infection or vaccination. Furthermore RBD and NTD antibodies 352 
were the focus of this study, therefore whether antibodies of other specificities mediate ADE warrants further study. 353 
Additionally, the macaque model has a rather short course of infection, thus effects of SARS-CoV-2 antibody on 354 









Finally, administration of COVID-19 convalescent sera to over 35,000 COVID-19 patients have demonstrated 356 
the treatment to be safe and is not associated with enhanced disease (Joyner et al., 2020). Of greater importance is 357 
that both the Pfizer/BioNTech and Moderna mRNA-lipid nanoparticle (LNP) vaccine efficacy trials have 358 
completed and showed ~95% vaccine efficacy (Jackson et al., 2020; Polack et al., 2020). That the Moderna 359 
mRNA-LNP COVID-19 vaccine efficacy trial had 30 severe cases of COVID-19 occur—all in the placebo group 360 
(Baden et al., 2021), demonstrated that if ADE of infection or lung pathology will occur in humans with 361 
vaccination, it will be rare. A recent study demonstrated that suboptimal neutralizing Ab level is a significant 362 
predictor of severity for SARS-CoV-2 (Garcia-Beltran et al., 2020). Thus, even with the rarity of sever  lung 363 
pathology associated with presence of anti-spike Ab in animal model studies reported here, it will be important to 364 
continue to monitor on-going COVID-19 vaccination for the possibility of vaccine associated enhanced disease 365 
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Figure 1. SARS-CoV-2 receptor-binding domain (RBD) and N-terminal domain (NTD) Abs mediate 411 
enhancement of infection.  412 
(A-B) Timeline of blood sampling, plasmablasts and/or antige -specific memory B cells (MBC) sorting, and Ab 413 
isolation from convalescent (A) SARS-CoV-2 and (B) SARS-CoV donors.  414 
(C) Summary of number and specificity of Abs isolated from each donor. 415 
(D-E) In vitro neutralization curves for NTD infection-enhancing Abs against (D) pseudotyped SARS-CoV-2 416 
D614G in 293T-hACE2 cells, and (E) replication-competent nano-luciferase (nLuc) SARS-CoV-2 in Vero cells. 417 
(F-J) FcγR-dependent pseudotyped SARS-CoV-2 infection-enhancement when RBD Abs or mock medium control 418 
was added to (F) parental TZM-bl cells, and TZM-bl cells stably expressing human FcγR receptors (G) FcγRI, (H) 419 
FcγRIIa, (I) FcγRIIb or (J) FcγRIII.  420 
(K-L) The effect of RBD Ab fragment antigen-binding regions (Fabs) on pseudotyped SARS-CoV-2 D614G 421 
infection was tested in (K) FcγRI-expressing TZM-bl cells and (L) FcγRIIb-expressing TZM-bl cells. Data are 422 
represented as mean±SEM. Three or four independent experiments were performed and representative data are 423 
shown. 424 
Figure 2. Structural and phenotypic characterization of infection-enhancing and non-infection-enhancing 425 
RBD and NTD Abs. 426 
(A) Summary of Ab epitope, binding, and neutralizing or infection-enhancing activity in ACE2-positive/FcγR-427 
negative cells or ACE2-negative/FcγR-positive cells. Ab functions are color-coded based on the key shown at the 428 
right. MN titer, micro-neutralization titer; ND, not determined. 429 
(B-E) 3D reconstruction of negative stain electron microsopy images of stabilized SARS-CoV-2 S ectodomain 430 
trimers (S-2P; gray) bound to the Fabs (various colors) of (B,D) infection-enhancing or (C,E) non-infection-431 
enhancing RBD or NTD antibodies.  432 
Figure 3. Simultaneous binding of infection-enhancing and non-infection enhancing Abs to individual S 433 
trimers. 434 
(A) Cross-blocking activity of RBD and NTD neutralizing Abs tested by surface plasmon resonance (SPR). S-2P 435 
was captured by one Ab (Y-axis) followed by binding by the second Ab (X-axis).  436 
(B) 3D reconstruction of simultaneous recognition of SAR -CoV-2 S-2P by two RBD Abs DH1041+DH1047, or 437 









(C) Cross-blocking activity of neutralizing Abs and infection-enhancing NTD Abs tested by SPR and shown as i  439 
(A).  440 
(D-F) 3D reconstruction of SARS-CoV-2 S-2P simultaneously bound (D) NTD Abs DH1053 and DH1050.1, (E) 441 
RBD infection-enhancing Ab and a NTD non-infection-e hancing Ab, or (F) triple-Ab combinations of RBD Ab442 
DH1043, RBD Ab DH1047, and either NTD Ab DH1051 (left) or DH1050.1 (right). 443 
(G-H) RBD Ab neutralization of SARS-CoV-2 D614G pseudovirus infection of 293T/ACE2 cells in the presence 444 
of 1:132 or 1:1,325 ratios of excess infection-enhancing NTD Ab DH1052.  445 
Figure 4. Cryo-electron microscopy of neutralizing and non-neutralizing Abs in complex with SARS-CoV-2 446 
Spike ectodomain. Structures of SARS-CoV-2 S protein in complex with RBD Abs (A) DH1041 (red), (B) 447 
DH1043 (pink), (C) DH1047 (magenta), (D) neutralizing NTD Ab DH1050.1 (blue), and (E) infection-enhancing 448 
NTD Ab DH1052 (green). Each Ab is bound to S-2P shown in gray with its RBM colored purple blue. (Right) 449 
Zoomed-in views of the Ab interactions with S-2P trimers. The Ab complementarity determining (CDR) loops are 450 
colored: HCDR1 yellow, HCDR2 limon, HCDR3 cyan, LCDR1 orange, LCDR2 wheat and LCDR3 light blue. See 451 
also Supplemental Data 1. 452 
Figure 5. NTD Ab DH1052 does not always enhance SARS-CoV-2 replication or disease in vivo.  453 
(A-F) DH1052 passive immunization and murine SARS-CoV-2 challenge (A) study design, (B) body weight, (C) 454 
survival, (D) Hemorrhagic scores, (E) lung viral titers, and (F) SARS-CoV-2 envelope (E) and nucleocapsid (N) 455 
gene subgenomic RNA (sgRNA). 456 
(G-Q) Reduction of SARS-CoV-2 replication and disease in cynomolgus macaques by prophylactic administration 457 
of an NTD neutralizing Ab DH1050.1 or an NTD in vitro infection-enhancing Ab DH1052.  458 
(G) DH1050.1 and DH1052 prophylaxis cynomolgus macaque (n=5 per group) study design. CH65 was used as a 459 
negative control Ab.  460 
(H-I) Serum human IgG concentrations at (H) Day -5 and (I) Day 2. 461 
(J-K) Day 2 serum neutralization titers shown as the recip o al serum dilution that inhibits 50% (ID50) of (J) 462 
pseudotyped SARS-CoV-2 replication in 293T/ACE2 cells or (K) SARS-CoV-2 replication in Vero cells. 463 
(L-M) Lung histopathology four days post infection. Lung sections were scored for (L) inflammation by 464 
hematoxylin and eosin (H&E) staining, and for (M) the presence of SARS-CoV-2 nucleocapsid by 465 









(N-Q) Viral load quantified as SARS-CoV-2 E gene sgRNA and N gene sgRNA in (N-O) bronchoalveolar lavage 467 
(BAL) or (P-Q) nasal swab fluid on Day 2 and Day 4 post challenge. LOD, limit of detection. Statistical 468 
significance in all the panels were determined using Wilcoxon rank sum exact test. Horizontal bars are the group 469 
mean. Asterisks show the statistical significance between indicated group and CH65 control group: ns, not 470 
significant, *P<0.05, **P<0.01, ***P<0.001. 471 
Figure 6. RBD Abs that mediate FcγR-dependent infection-enhancement in vitro, protect mice from SARS-472 
CoV-2 or bat WIV1-CoV challenge. 473 
(A-B) Protection of BALB/c mice (n=5 per group) from mouse-adapted SARS-CoV-2 (SARS-CoV-2 2AA MA) by 474 
(A) prophylactic or (B) therapeutic RBD and/or NTD Ab administration. Ab CH65 served as a negative control. 475 
Titers of infectious virus in the lung were examined 48h post-infection.  476 
(C) Maximum likelihood tree of Spike amino acid sequences for SARS-related group 2B and group 2C 477 
coronaviruses. 478 
(D) Monoclonal RBD, NTD and S2 Ab ELISA binding titer for soluble S protein ectodomains from human and 479 
animal coronaviruses. Titers are log area-under-the-curve (AUC).  480 
(E) SARS-CoV and bat WIV1-CoV cross-neutralization titers for cross-reactive RBD and S2 Abs. 481 
(F-G) Protection of HFH4-hACE2-transgenic mice (n=5 per group) from SARS-related bat WIV1-CoV challenge 482 
by (A) prophylactic or (B) therapeutic RBD Ab administration. Lung viral titers were examined at 48 post-infection. 483 
Statistical significance in all the panels were determined using Wilcoxon rank sum exact test. Horizontal bars are 484 
the group mean. Asterisks show the statistical significa ce between indicated group and CH65 control gup: ns, 485 
not significant, *P<0.05, **P<0.01.  486 
Figure 7. RBD Abs that mediate FcγR-dependent infection enhancement in vitro, protect non-human 487 
primates from SARS-CoV-2 challenge. 488 
(A) Cynomolgus macaques (n=5 per group) RBD Ab SARS-CoV2 challenge study design. DH1041, DH1043, 489 
DH1046, DH1047 or an irrelevant CH65 were infused into macaques.  490 
(B-C) Serum human IgG concentrations at Day -5 (B) and Day 2 (C). 491 
(D-E) Day 2 serum neutralization titers shown as the recip o al serum dilution that inhibits 50% (ID50) of (D) 492 









(F-G) Lung histopathology for (F) inflammation by H&E staining and (G) the presence of SARS-CoV-2 494 
nucleocapsid by IHC staining 4 days post-challenge. 495 
(H-K) Viral load quantified as SARS-CoV-2 E gene sgRNA and N gene sgRNA in (H-I) bronchoalveolar lavage 496 
(BAL) or (J-K) nasal swab fluid on Day 2 and Day 4 post challenge.  497 
Statistical significance in all the panels were determined using Wilcoxon rank sum exact test. Horizontal bars are 498 
the group mean. Asterisks show the statistical significa ce between indicated group and CH65 control gup: ns, 499 




STAR METHODS 504 
KEY RESOURCES TABLE 505 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
PE-Cy5 Mouse Anti-Human CD3, Clone# HIT3a BD Biosciences Cat#555341; RRID: 
AB_10698936 
BV605 Mouse Anti-Human CD14, Clone# M5E2  Biolegend Cat#301834, RRID: 
AB_2563798  
BV570 Mouse Anti-Human CD16, Clone# 3G8  Biolegend Cat# 302035, RRID: 
AB_2632790  
APC-Cy7 Mouse Anti-Human CD19, Clone# SJ25C1 BD Biosc ences Cat# 557791, RRID: 
AB_396873 
FITC Mouse Anti-Human IgD, Clone# IA6-2 BD Biosciences Cat# 555778, RRID: 
AB_396113 
PerCp-Cy5.5 Mouse Anti-Human IgM, Clone# G20-127  BD Biosciences Cat# 561285, 
RRID:AB_10611998 
PE-CF594, Mouse Anti-Human CD10, Clone# HI10A BD Biosciences  Cat# 562396, RRID: 
AB_11154416 
PE-Cy5 Mouse Anti-Human CD235a, Clone# GA-R2 BD Biosc ences Cat# 559944, RRID: 
AB_397387 
PE-Cy7 Mouse Anti-Human CD27, Clone# O323 eBioscience Cat# 25-0279, RRID: 
AB_1724039 
APC-AF700 Mouse Anti-Human CD38, Clone# LS198-
4-2 
Beckman Coulter  Cat# B23489, RRID: 
NA 
SARS-CoV/SARS-CoV-2 Spike Ab, Clone# D001 Sino Biological Cat #40150-D001 
Anti-influenza virus hemagglutinin human IgG CH65 (Whittle et al., 2011) NA 
Rabbit polyclonal SARS-CoV-2 nucleocapsid Ab GeneTex Cat #GTX135357, 
RRID:AB_2868464 
Rat anti-human CD3, Clone# CD3-12 Bio-Rad Cat #MCA1477, 
RRID:AB_321245 










Rabbit anti-human CD68 polyclonal Ab Sigma-Millipore Cat# HPA048982, 
RRID: AB_2680587 
Rabbit anti-human CD163, Clone# EPR19518 Abcam Cat# ab182422, 
RRID: AB_2753196 
Mouse anti-human HLA-DP/DQ/DR, Clone# CR3/43 Dako Cat# M0775, RRID: 
AB_2313661 
Rabbit anti-human CD11b, Clone# EP1345Y Abcam Cat# ab52478, RRID: 
AB_868788 
HRP goat anti-human IgG SouthernBiotech Cat #2040-05, 
RRID:AB_2795644 
HRP goat anti-rabbit IgG Abcam Cat #ab97080, 
RRID:AB_10679808 
Biotin mouse anti-human IgG Fc, Clone# H2  Southern Biotech Cat# 9042-08, 
RRID:AB_2796608 
Bacterial and Virus Strains 
SARS-CoV-2 D614G pseudotyped virus (Korber et al., 2020) NA 
SARS-CoV-2 virus, Isolate USA-WA1/2020 BEI Resources Cat #NR-52281 
SARS-CoV-2 nanoLuc virus (Hou et al., 2020) NA 
SARS-CoV nanoLuc virus (Sheahan et al., 
2017) 
NA 
WIV1-CoV nanoLuc virus (Menachery et al., 
2016) 
NA 
SARS-CoV-2 moues-adapted virus 2AA MA (Dinnon et al., 2020) NA 
SARS-CoV-2 moues-adapted virus MA10 (Leist et al., 2020a) NA 
Biological Samples   
Plasma, PBMCs, nasal swabs and bronchoalveolar 
lavage (BAL) from macaques 
This paper NA 
Chemicals, Peptides, and Recombinant Proteins 
LIVE/DEAD Fixable Red Dead Cell Stain Kit Thermo Fisher 
Scientific 
Cat#L34972 
SuperScript III Reverse Transcriptase Invitrogen Cat #18080085 
dNTP Set, PCR Grade New England 
Biolabs 
Cat # N0447L 
UltraPure DNase/RNase-Free Distilled Water Invitrogen Cat #10977 
GeneLink Random Hexamer Primers GeneLink Cat #26-4000-03 
AmpliTaq Gold 360 Mastermix Thermo Fisher 
Scientific 
Cat #4398881 
Expi293 media  Invitrogen Cat #A1435102 
Expifectamine  Life Technologies  Cat #A14524 









SureBlue Reserve tetramethylbenzidine substrate KPL Cat #5120-0081 
TaqMan Fast Virus 1-Step Master Mix ThermoFisher 4444434 
QIAsymphony DSP Virus/Pathogen Midi Kit Qiagen 937055 
NucleoSpin Gel and PCR Clean-Up Takara 740609.5 
MEGAscript T7 Transcription Kit ThermoFisher AM1334 
MEGAclear Transcription Clean-Up Kit ThermoFisher AM1908 
Luciferase Cell Culture Lysis 5x Reagent  Promega Cat# E1531 
Background Reducing Ab Diluent  Agilent Cat# S3022 










Human ACE2 soluble protein (Edwards et al., 
2021) 
NA 
SARS-CoV-2 Spike S1+S2 ectodomain (ECD) Sino Biological Cat #40589-V08B1 
SARS-CoV-2 Spike S2 ECD Sino Biological Cat #40590-V08B 
SARS-CoV-2 Spike RBD from insect cell sf9 Sino Biological Cat #40592-V08B 
SARS-CoV-2 Spike RBD from mammalian cell 293 Sino Bi logical Cat #40592-V08H 
SARS-CoV Spike Protein DeltaTM BEI Resources Cat #NR-722 
SARS-CoV WH20 Spike RBD Sino Biological Cat #40150-V 8B2 
SARS-CoV WH20 Spike S1 Sino Biological Cat #40150-V8B1 
MERS-CoV Spike S1+S2 Sino Biological Cat #40069-V08B 
MERS-CoV Spike S1 Sino Biological Cat #40069-V08B1 
MERS-CoV Spike S2 Sino Biological Cat #40070-V08B 
MERS-CoV Spike RBD Sino Biological Cat #40071-V08B1 
SARS-CoV CL Protease protein BEI Resources Cat #30105 
SARS-CoV Membrane (M) protein BEI Resources Cat #110705 
SARS-CoV-2 Spike NTD (Zhou et al., 2020b) NA 
SARS-CoV Spike RBD (Hauser et al., 2020) NA 
MERS-CoV Spike RBD (Hauser et al., 2020) NA 
SARS-CoV-2 Spike-2P (Edwards et al., 
2021) 
NA 
SARS-CoV-2 Spike-HexaPro (Edwards et al., 
2021) 
NA 
Critical Commercial Assays 
MILLIPLEX MAP Non-Human Primate 




Bright-Glo Luciferase Assay System Promega Cat #2650 
Britelite Luminescence Reporter Gene Assay System PerkinElmer Life 
Sciences 
Cat #6066761 
Nano-Glo Luciferase Assay System  Promega Cat #N1150 
Deposited Data 
Structure of SARS-CoV-2 S protein in complex with 
Receptor Binding Domain Ab DH1041 
This paper PDB 7LAA, EMD- 
23246 
Structure of SARS-CoV-2 S protein in complex with 
Receptor Binding Domain Ab DH1047 
This paper PDB 7LD1, EMD- 
23279 
Structure of SARS-CoV-2 S protein in complex with N-
terminal domain Ab DH1050.1 
This paper PDB 7LCN, EMD- 
23277 
Structure of SARS-CoV-2 S protein in complex with N-
terminal domain Ab DH1052 
This paper PDB 7LAB, EMD- 
23248 
SARS-CoV-2 Spike Protein Trimer bound to DH1043 
fab 
This paper PDB 7LJR, EMD- 
23400 
Negative stain EM structure of Ab DH1041 Fab in 
complex with SARS-CoV-2 Hexapro spike 
This paper EMD-22920 
Negative stain EM structure of Ab DH1042 Fab in 
complex with SARS-CoV-2 2P spike 
This paper EMD-22921 
Negative stain EM structure of Ab DH1043 Fab in 
complex with SARS-CoV-2 Hexapro spike 
This paper EMD-22923 
Negative stain EM structure of Ab DH1044 Fab in 
complex with SARS-CoV-2 2P spike 
This paper EMD-22929 
Negative stain EM structure of Ab DH1045 Fab in 
complex with SARS-CoV-2 Hexapro spike 
This paper EMD-22930 









complex with SARS-CoV-2 Hexapro spike 
Negative stain EM structure of Ab DH1048 Fab in 
complex with SARS-CoV-2 Hexapro spike 
This paper EMD-22936 
Negative stain EM structure of Ab DH1049 Fab in 
complex with SARS-CoV-2 2P spike 
This paper EMD-22942 
Negative stain EM structure of Ab DH1050.1 Fab in 
complex with SARS-CoV-2 Hexapro spike 
This paper EMD-22944 
Negative stain EM structure of Ab DH1050.2 Fab in 
complex with SARS-CoV-2 2P spike 
This paper EMD-22945 
Negative stain EM structure of Ab DH1051 Fab in 
complex with SARS-CoV-2 Hexapro spike 
This paper EMD-22946 
Negative stain EM structure of Ab DH1053 Fab in 
complex with SARS-CoV-2 2P spike in the 1-RBD-up 
state 
This paper EMD-22947 
Negative stain EM structure of Ab DH1053 Fab in 
complex with SARS-CoV-2 2P spike in the 3-RBD-
down state 
This paper EMD-22948 
Negative stain EM structure of Ab DH1054 Fab in 
complex with SARS-CoV-2 2P spike 
This paper EMD-22951 
Negative stain EM structure of Ab DH1055 Fab in 
complex with SARS-CoV-2 2P spike 
This paper EMD-22952 
Negative stain EM structure of Ab DH1056 Fab in 
complex with SARS-CoV-2 2P spike 
This paper EMD-22953 
Negative stain EM structure of Ab Fabs DH1043 and 
DH1051 in complex with SARS-CoV-2 2P spike 
This paper EMD-22955 
Negative stain EM structure of Ab Fabs DH1041 and 
DH1051 in complex with SARS-CoV-2 2P spike 
This paper EMD-22956 
Negative stain EM structure of Ab Fabs DH1043 and 
DH1047 in complex with SARS-CoV-2 2P spike 
This paper EMD-22957 
Negative stain EM structure of Ab Fabs DH1047 and 
DH1051 in complex with SARS-CoV-2 2P spike 
This paper EMD-22958 
Negative stain EM structure of Ab Fabs DH1045 and 
DH1050.1 in complex with SARS-CoV-2 2P spike 
This paper EMD-22969 
Negative stain EM structure of Ab Fabs DH1043 and 
DH1050.1 in complex with SARS-CoV-2 2P spike 
This paper EMD-22970 
Negative stain EM structure of Ab Fabs DH1041 and 
DH1047 in complex with SARS-CoV-2 2P spike 
This paper EMD-22971 
Negative stain EM structure of Ab Fabs DH1050.1 and 
DH1053 in complex with SARS-CoV-2 2P spike 
This paper EMD-22984 
Negative stain EM structure of Ab Fabs DH1043, 
DH1047 and DH1050.1 in complex with SARS-CoV-2 
2P spike 
This paper EMD-22985 
Negative stain EM structure of Ab Fabs DH1043, 
DH1047 and DH1051 in complex with SARS-CoV-2 2P 
spike 
This paper EMD-22986 
Experimental Models: Cell Lines 
TZM-bl NIH, ARRRP Cat #8129 
TZM-bl expressing FcγRI (Perez et al., 2009) NA 
TZM-bl expressing FcγRIIa (Perez et al., 2009) NA 
TZM-bl expressing FcγRIIb (Perez et al., 2009) NA 
TZM-bl expressing FcγRIII (Perez et al., 2009) NA 
Expi 293i Invitrogen Cat #14527 









Vero E6 ATCC Cat# CRL-1586 
Experimental Models: Organisms/Strains 
BALB/c mouse Envigo NA 
HFH4-hACE2 transgenic mice (Menachery et al., 
2016) 
NA 
Cynomolgus macaques BioQUAL NA 
Oligonucleotides 






























VH1 Leader-A 5'- AGGTTCCTCTTTGTGGTGGCAG 




VH1 Leader-A 5'- 





VH1 Leader-A 5'- 





VH1 Leader-A 5'- 










VH1 Leader-A 5'- 





VH1 Leader-A 5'- GGTGGCATTGGAGGGAATGTT -

























































VH1 Leader-A 5'- 





VH1 Leader-A 5'- ATGAAACACCTGTGGTTCTTCC 
























VH1 Leader-A 5'- GGCAGCAGCAACAGGTGCCCA -












































VH1 Leader-A 5'- GTTCTGTGGTTTCTTCTGAGCTG 







































VH1-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACCAGGTGCA

















CTTGARGGAGTCTGGTCC -3' (PCRb primer) 
VH3-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACGAGGTKCA




VH4-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACCAGGTGCA




VH5-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACGARGTGCA




VH6-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACCAGGTACA


































VK1-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACGACATCCA




VK2-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACGATATTGT




VK3-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACGAAATTGT




VK4-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACGACATCGT




VK5-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACGAAACGAC




VK6-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACGAAATTGT




VK7-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACGACATTGT









VL1-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACCAGTCTGT












VL2-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACCAGTCTGC




VL3-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACTCYTATGA




VL3l-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACTCTTCTGA




VL4ab-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACCAGCYTGT




VL4c-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACCTGCCTGT




VL5,9-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACCAGSCTGT




VL6-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACAATTTTAT




VL7,8-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACCAGRCTGT




VL10-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACCAGGCAGG




























































VH1 Leader-A 5'- AGGTTCCTCTTTGTGGTGGCAG 




VH1 Leader-A 5'- 













VH1 Leader-A 5'- 





VH1 Leader-A 5'- 










VH1 Leader-A 5'- 





VH1 Leader-A 5'- GGTGGCATTGGAGGGAATGTT -

















































VH1 Leader-A 5'- 





VH1 Leader-A 5'- ATGAAACACCTGTGGTTCTTCC 
























VH1 Leader-A 5'- GGCAGCAGCAACAGGTGCCCA -




























(PCRa primer) Scientific 




















VH1 Leader-A 5'- GTTCTGTGGTTTCTTCTGAGCTG 







































VH1-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACCAGGTGCA




VH2-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACCAGRGCAC




VH3-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACGAGGTKCA




VH4-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACCAGGTGCA




VH5-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACGARGTGCA




VH6-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACCAGGTACA



































AGAGGCTCAG -3' (PCRb primer) 
IgA2-int 5'- 
GGGCCGCTGTGCCCCCAGAGGTGCTGGTGCTGT




VK1-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACGACATCCA




VK2-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACGATATTGT




VK3-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACGAAATTGT




VK4-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACGACATCGT




VK5-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACGAAACGAC




VK6-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACGAAATTGT




VK7-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACGACATTGT









VL1-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACCAGTCTGT




VL2-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACCAGTCTGC




VL3-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACTCYTATGA




VL3l-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACTCTTCTGA




VL4ab-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACCAGCYTGT




VL4c-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACCTGCCTGT




VL5,9-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACCAGSCTGT




VL6-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACAATTTTAT




VL7,8-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACCAGRCTGT












VL10-Int tag 5'- 
CTGGGTTCCAGGTTCCACTGGTGACCAGGCAGG






























SARS-CoV-2 or WIV1-CoV E gene subgenomic RNA 
primer/probe: 
forward primer: 5’-CGATCTCTTGTAGATCTGTTCT 
C-3’;  





SARS-CoV-2 N gene subgenomic RNA primer/probe: 







WIV1-CoV N gene subgenomic RNA primer/probe: 
forward primer: 5’-CGATCTCTTGTAGATCTGTTCT 
C-3’;  





SARS-CoV-2 total viral RNA E gene primer/probe: 
forward primer: 5’-ACAGGTACGTTAATAGTTAATA 
GCGT-3’,  






HV1301409_4A (human IgG1_4A heavy chain 
backbone) 
Genscript NA 
pH510049_VRC_LS.v2 (human IgG1_LS heavy chain 
backbone) 
Genscript NA 
HV1301410 (human kappa chain backbone) Genscript NA 
HV1301414.v2 (human lambda chain backbone) Genscript NA 
pcDNA3.1-SARS-CoV-2_SgE (for making subgenomic 
RNA standard RNA) 
Genscript 
NA 
pcDNA3.1-SARS-CoV-2_SgN (for making subgenomic 











pcDNA3.1-WIV1-CoV_SgN (for making subgenomic 
RNA standard RNA) 
Genscript 
NA 




























SAS v9.4 SAS Institute NA 
Cloanalyst Program (Kepler et al., 2014) NA 
Biacore S200 Evaluation software Cytiva NA 
Coot (Emsley et al., 2010) Version 0.8.9.2 
Relion (Scheres, 2012; 
Scheres, 2016) 
Version 3.1 
Phenix (Afonine et al., 
2018; Liebschner et 
al., 2019)  
Version 1.17 




ISOLDE  (Croll, 2018) Version 1.1 










Leginon system  (Suloway et al., 
2005). 
NA 
cryoSPARC (Punjani et al., 2017) https://cryosparc.com 
Bio-Plex Manager Software Bio-Rad NA 
Adobe Illustrator 2020 Adobe NA 
Adobe Photoshop CC 2019 Adobe NA 
Other 
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RESOURCE AVAILABILITY  507 









Further information and requests for reagents should be directed and will be fulfilled by the Lead Contact 509 
Kevin O. Saunders (kevin.saunders@duke.edu). 510 
Materials availability 511 
Abs and other reagents generated in this study are available from the Lead Contact with a completed Materi ls 512 
Transfer Agreement.  513 
Data and code availability  514 
The data that support the findings of this study are available from the corresponding authors on request. 515 
Additional Supplemental Items are available from Mend ley Data at http://dx.doi.org/10.17632/9y6p7shshy.1. 516 
 517 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 518 
Human Subjects 519 
Nasopharyngeal swabs and peripheral blood samples were collected from a convalescent COVID-19 donor 520 
(MESSI ID #450905) on designated days after reported onset of COVID symptoms. The SARS-CoV donor PBMC 521 
were provided by NIH/VRC. Human subject specimens were collected and used with the informed consent of s udy 522 
participants and in compliance with the Duke University Medical Center Institutional Review Board (DUHS IRB 523 
Pro00100241). 524 
 525 
Symptom data collections  526 
Participant self-reported symptoms were recorded at each time-point for 39 symptom categories (nasal 527 
discharge, nasal congestion, sneezing, coughing, shortness of breath, malaise, throat discomfort, fever, h adache, 528 
shaking chills, loss of smell, loss of taste, excessive sweating, dizziness, pain behind the eyes, itchy/watery eyes, 529 
visual blurring, hearing problems, ear pain, confusion, stiff neck, swollen glands, palpitations, chest pain, pain in 530 
joints, muscle soreness, fatigue, loss of appetite, abdominal pain, nausea/vomiting, diarrhea, swelling, itchy skin, 531 
rash, skin lesions, unusual bleeding, red fingers or toes, red eyes, other: specify). Each symptom was scored on a 532 
scale of 0–4, with 0 indicating not present, 1 mild, 2 moderate, 3 severe, and 4 very severe symptoms. Daily 533 
symptom count (number of non-zero symptom categories) and symptom severity (sum of all symptom scores) were 534 









“historical” symptom survey recorded maximum score f r each symptom category between symptom onset and 536 
study enrollment.  537 
 538 
Non-human primate model 539 
In total, 62 outbred adult male and female cynomolgus macaques (Macaca fascicularis), 2-4 kg body weight, 540 
were randomly allocated to groups. The study protocol and all veterinarian procedures were approved by the 541 
Bioqual IACUC per a memorandum of understanding with the Duke IACUC, and were performed based on 542 
standard operating procedures. Macaques studied were housed and maintained in an Association for Assessm nt 543 
and Accreditation of Laboratory Animal Care-accredit  institution in accordance with the principles of the 544 
National Institute of Health. All studies were carried out in strict accordance with the recommendations n the 545 
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health in BIOQUAL (Rockville, 546 
MD). BIOQUAL is fully accredited by AAALAC and through OLAW, Assurance Number A-3086. All physical 547 
procedures associated with this work were done under an sthesia to minimize pain and distress in accordance with 548 
the recommendations of the Weatherall report, “The use of non-human primates in research.” Teklad 5038 Primate 549 
Diet was provided once daily by animal size and weight. The diet was supplemented with fresh fruit andvegetables. 550 
Fresh water was given ad libitum. All monkeys were maintained in accordance with the Guide for the Care and Use 551 
of Laboratory Animals. 552 
 553 
Mouse models 554 
Eleven to twelve-month old female immunocompetent BAL /c mice purchased from Envigo (BALB/c 555 
AnNHsd, stock# 047) were used for SARS-CoV-2 in vivo protection experiments as described previously (Dinnon 556 
et al., 2020; Leist et al., 2020a). Ten-week-old HFH4-hACE2 transgenic mice were bred and maintained at the 557 
University of North Carolina at Chapel Hill and used for WIV-1 in vivo protection experiments. Mice were housed 558 
in groups of five animals per cage and fed standard chow diet. The study was carried out in accordance with the 559 
recommendations for care and use of animals by the Office of Laboratory Animal Welfare (OLAW), National 560 
Institutes of Health and the Institutional Animal Care. All mouse studies were performed at the Univers ty of North 561 
Carolina (Animal Welfare Assurance #A3410-01) using protocols (19-168) approved by the UNC Institutional 562 










METHOD DETAILS 565 
Expression of Recombinant Viral Proteins 566 
The SARS-CoV-2 ectodomain constructs were produce and purified as describe previously (Wrapp, D.et al. 567 
2020). Plasmids encoding Spike-2P and HexaPro (Hsieh et al., 2020) were transiently transfected in FreeStyle 293 568 
cells (Thermo Fisher) using Turbo293 (SpeedBiosystem ). The cultures were collected on Day 6 post transfection. 569 
The cells were separated from the medium by centrifugation. Protein were purified from filtered cell supernatants 570 
by StrepTactin resin (IBA) and additionally by size exclusive chromatography using Superose 6 10/300 increase 571 
column (GE Healthcare) in 2mM Tris pH 8, 200mMnNaCl, 0.02% NaN3. SARS-CoV-2 NTD was produced as 572 
previously described (Zhou et al., 2020b). SARS-CoV RBD and MERS-CoV Spike RBD were cloned into pVRC 573 
vector for mammalian expression (FreeStyle 293F or Expi293F suspension cells). The construct contains n HRV 574 
3C-cleavable C-terminal SBP-8xHis tag. Supernatants were harvested 5 days post-transfection and passaged 575 
directly over Cobalt-TALON resin (Takara) followed by size exclusion chromatography on Superdex 200 Increase 576 
(GE Healthcare) in 1x PBS. Typical yields from FreeStyle 293F cells are approximately 50 mg/liter culture. 577 
Affinity tags can be removed using HRV 3C protease (ThermoScientific) and the protein repurified using Cobalt-578 
TALON resin to remove the protease, tag and non-cleaved protein.  579 
 580 
Antigen-Specific Single B Cell Sorting 581 
Plasmablasts were sorted by flow cytometry from the SARS-CoV-2 donor on Day 11 and Day 15 post 582 
symptom onset. PBMCs were stained with optimal concentrations of the following fluorochrome-Ab conjugates: 583 
IgD PE (Clone# IA6-2, BD Biosciences, Catalog# 555779), CD3 PE-Cy5 (Clone# HIT3a, BD Biosciences, 584 
Catalog# 555341), CD10 PE-CF594 (Clone# HI10A, BD Biosciences, Catalog# 562396), CD27 PE-Cy7 (Clone# 585 
O323, eBioscience, Catalog# 25-0279), CD38 APC-Alexa Fluor (AF) 700 (Clone# LS198-4-2, Beckman Coulter, 586 
Catalog# B23489), CD19 APC-Cy7 (Clone# LJ25C1, BD Biosciences, Catalog# 561743), CD16 BV570 (Clone# 587 
3G8, Biolegend, Catalog# 302035), CD14 BV605 (Clone# M5E2, Biolegend, Catalog# 301834), and CD20 BV650 588 
(Clone# 2H7, BD, Catalog# 563780). The cells were then labeled with Fixable Aqua Live/Dead Cell Stain K t 589 
(Invitrogen, Catalog# L34957). On a BD FACSAria II flow cytometer (BD Biosciences), plasmablasts were 590 









well plates containing lysis buffer. Sorted plates were frozen at -80°C in the DHVI Flow Facility under BSL3 592 
precautions in the Duke Regional Biocontainment Labor tory (Durham, NC) until processing. 593 
Antigen-specific memory B cells (MBCs) were isolated by flow cytometric sorting from the SARS-CoV-2 594 
donor on Day 36 post symptom onset, and a donor with SARS-CoV history. PBMCs were stained with IgD FITC 595 
(Clone# IA6-2, BD Biosciences, Catalog# 555778), IgM PerCp-Cy5.5 (Clone# G20-127, BD Biosciences, 596 
Catalog# 561285), CD10 PE-CF594 (Clone# HI10A, BD Biosciences, Catalog# 562396), CD3 PE-Cy5 (Clone# 597 
HIT3a, BD Biosciences, Catalog# 555341), CD235a PE-Cy5 (Clone# GA-R2, BD Biosciences, Catalog# 559944), 598 
CD27 PE-Cy7 (Clone# O323, eBioscience, Catalog# 25-0279), CD38 APC-AF700 (Clone# LS198-4-2, Beckman 599 
Coulter, Catalog# B23489), CD19 APC-Cy7 (Clone# LJ25C1, BD Biosciences, Catalog# 561743), CD14 BV605 600 
(Clone# M5E2, Biolegend, Catalog# 301834), CD16 BV570 (Clone# 3G8, Biolegend, Catalog# 302035), and 601 
fluorescent-labeled SARS-CoV-2 Spike probes (AF647-conjugated Spike-2P, PE-conjugated Spike-2P, AF647-602 
conjugated NTD, AF647-conjugated RBD, VioBright 515-conjugated RBD). The cells were then labeled with 603 
Fixable Aqua Live/Dead Cell Stain Kit (Invitrogen, Catalog# L34957). On a BD FACSAria II flow cytometer (BD 604 
Biosciences), antigen-specific MBCs were identified as viable CD3-/CD14-/CD16-/CD235a-/CD19+/IgD-/probe+ 605 
cells and were sorted as single cells into 96-well plates containing lysis buffer. Collection plates were immediately 606 
frozen in a dry ice/ethanol bath, and stored at -80 °C in the DHVI Flow Facility under BSL3 precautions in the 607 
Duke Regional Biocontainment Laboratory until processing. Flow cytometric data were analyzed using FlowJo 608 
version 10. 609 
 610 
PCR Amplification of Human Ab Genes 611 
Ab genes were amplified by RT-PCR from flow cytometry-sorted single B cells using the methods as 612 
described previously (Liao et al., 2009; Wrammert et al., 2008) with modification. The PCR-amplified genes were 613 
then purified and sequenced with 10 µM forward and reverse primers. Sequences were analyzed by using the 614 
human library in Cloanalyst for the VDJ arrangements of the immunoglobulin IGHV, IGKV, and IGLV sequences 615 
and mutation frequencies (Kepler et al., 2014). Clonal relatedness of VHDHJH and VLJL sequences was determined 616 
as previously described (Liao et al., 2013). 617 
 618 









Transient transfection of recombinant Abs was performed as previously described (Liao et al., 2009). Briefly, 620 
purified PCR products were used for overlapping PCR to generate linear human IgG expression cassettes. Th  621 
expression cassettes were transfected into 293i cells using ExpiFectamine (Thermo Fisher Scientific, Catalog# 622 
A14525). The supernatant samples containing recombinant IgGs were used for IgG quantification and preliminary 623 
ELISA binding screening. 624 
The down-selected human Ab genes were then synthesized and cloned (GenScript) in a human IgG1 backbone 625 
(HV1301409_4A) with 4A mutations to enhance Ab-dependent cell-mediated cytotoxicity (ADCC) or a human 626 
IgG1 backbone (pH510049_VRC_LS.v2) with a LS mutation o extent Ab half-life (Saunders, 2019). Recombinant 627 
IgG Abs were then produced in HEK293i suspension cells by transfection with ExpiFectamine and purified using 628 
Protein A resin. The purified IgG Abs were run in SDS-PAGE for Coomassie blue staining and western blot for 629 
quality control and then used for the downstream experiments. 630 
 631 
Ab Binding ELISA 632 
For ELISA binding assays of Coronavirus Spike Abs, the antigen panel included SARS-CoV-2 Spike S1+S2 633 
ectodomain (ECD) (SINO, Catalog # 40589-V08B1), SAR-CoV-2 Spike-2P (Wrapp et al., 2020b), SARS-CoV-2 634 
Spike S2 ECD (SINO, Catalog # 40590-V08B), SARS-CoV-2 Spike RBD from insect cell sf9 (SINO, Catalog # 635 
40592-V08B), SARS-CoV-2 Spike RBD from mammalian cell 293 (SINO, Catalog # 40592- V08H), SARS-CoV-636 
2 Spike NTD-Biotin, SARS-CoV Spike Protein DeltaTM (BEI, Catalog # NR-722), SARS-CoV WH20 Spike RBD 637 
(SINO, Catalog # 40150-V08B2), SARS-CoV WH20 Spike S1 (SINO, Catalog #40150-V08B1), SARS-CoV RBD, 638 
MERS-CoV Spike S1+S2 (SINO, Catalog # 40069-V08B), MERS-CoV Spike S1 (SINO, Catalog #40069-V08B1), 639 
MERS-CoV Spike S2 (SINO, Catalog #40070-V08B), MERS-CoV Spike RBD (SINO, Catalog #40071-V08B1), 640 
MERS-CoV Spike RBD. In preliminary ELISA screening of the transient transfection supernatants, we also 641 
screened the Abs against SARS-CoV CL Protease protein (BEI, Catalog # 30105) and SARS-CoV Membrane (M)642 
protein (BEI, Catalog # 110705). 643 
For binding ELISA, 384-well ELISA plates were coated with 2 µg/mL of antigens in 0.1 M sodium 644 
bicarbonate overnight at 4°C. Plates were washed with PBS + 0.05% Tween 20 and blocked with blocked with645 
assay diluent (PBS containing 4% (w/v) whey protein, 15% Normal Goat Serum, 0.5% Tween-20, and 0.05% 646 









starting at 100 µg/mL, or un-diluted transfection supernatant were added and incubated for 1 hour, followed by 648 
washing with PBS-0.1% Tween 20. HRP-conjugated goatanti-human IgG secondary Ab (SouthernBiotech, 649 
catalog# 2040-05) was diluted to 1:10,000 and incubated at room temperature for 1 hour. These plates were ashed 650 
four times and developed with tetramethylbenzidine substrate (SureBlue Reserve- KPL). The reaction was stopped 651 
with 1 M HCl, and optical density at 450 nm (OD450) was determined. 652 
 653 
Affinity Measurements 654 
SPR measurements of SARS-CoV-2 Ab Fab binding to Spike-2P or Spike-HexaPro proteins were performed 655 
using a Biacore S200 instrument (Cytiva, formerly GE Healthcare, DHVI BIA Core Facility, Durham, NC) in 656 
HBS-EP+ 1x running buffer. The Spike proteins were first captured onto a Series S Streptavidin chip to a level of 657 
300-400 RU for Spike-2P and 350-450 resonance units(RU) for Spike-HexaPro. The Ab Fabs were injected at 0.5 658 
to 500 nM over the captured S proteins using the single cycle kinetics injection mode at a flow rate of 50uL/min. 659 
Association phase was maintained with either 120 or 240 second injections of each Fab at increasing 660 
concentrations followed by a dissociation of 600 seconds after the final injection. After dissociation, the S proteins 661 
were regenerated from the streptavidin surface using a 30 second pulse of Glycine pH1.5. Results were analyzed 662 
using the Biacore S200 Evaluation software (Cytiva). A blank streptavidin surface along with blank buffer binding 663 
were used for double reference subtraction to account f r non-specific protein binding and signal drift. Subsequent 664 
curve fitting analyses were performed using a 1:1 Langmuir model with a local Rmax for the Fabs with the665 
exception of DH1050.1 Fab which was fit using the heterogeneous ligand model with local Rmax. The report d 666 
binding curves are representative of two data sets.667 
 668 
Surface Plasmon Resonance Ab Blocking Assay 669 
RBD and NTD Abs binding to S protein was measured by surface plasmon resonance (BIAcore 3000; Cytiva, 670 
formerly GE Healthcare, DHVI BIA Core Facility, Durham, NC) analysis. Ab binding competition and blocking 671 
were measured by SPR following immobilization by amine coupling of monoclonal Abs to CM5 sensor chips 672 
(BIAcore/Cytiva). Ab competition experiments were performed by mixing S protein and mAb (30 minutes 673 
incubation) followed by injection for 5 minutes at 50µL/min. In separate assays and from analysis of binding to an 674 









saturation. Ab blocking assays were performed by co-injecting S protein (20 µM) over mAb immobilized surfaces 676 
for 3 minutes at 30 µL/min and a test Ab (200 µM) for 3 minutes at 30 µL/min. The dissociation of the Ab 677 
sandwich complex with the spike protein was monitored for 10 minutes with buffer flow and then a 24 second 678 
injection of Glycine pH2.0 for regeneration. Blank buffer binding was used for subtraction to account for signal 679 
drift. Data analyses were performed with BIA-evaluation 4.1 software (BIAcore/Cytiva).  680 
 681 
ACE2-blocking assay 682 
For ACE-2 blocking assays, plates were coated as stated above with 2 ug/mL recombinant ACE-2 protein, then 683 
washed and blocked with 3% BSA in 1X PBS. While assay plates blocked, purified Abs were diluted as stated 684 
above, only in 1% BSA with 0.05% Tween-20. In a separate dilution plate Spike-2P protein was mixed with the 685 
Abs at a final concentration equal to the EC50 at which spike binds to ACE-2 protein. The mixture was allowed to 686 
incubate at room temperature for 1 hour. Blocked assay plates were then washed and the Ab-spike mixture was 687 
added to the assay plates for a period of 1 hour at room temperature. Plates were washed and a polyclonal rabbit 688 
serum against the same Spike-2P protein was added for 1 hour, washed and detected with goat anti rabbit-HRP 689 
(Abcam cat# ab97080) followed by TMB substrate. Theextent to which Abs were able to block the binding spike 690 
protein to ACE-2 was determined by comparing the OD of Ab samples at 450 nm to the OD of samples containi g 691 
spike protein only with no Ab. The following formula was used to calculate percent blocking: blocking% = (100 - 692 
(OD sample/OD of spike only)*100). 693 
 694 
Negative-stain electron microscopy 695 
For each Fab-spike complex, an aliquot of spike protein at ~1-5 mg/ml concentration that had been flash 696 
frozen and stored at -80 °C was thawed in an alumin block at 37 °C for 5  minutes; then 1-4 µl of spike was 697 
mixed with sufficient Fab to give a 9:1 molar ratio of Fab to spike and incubated for 1 hour at 37 °C. The complex 698 
was then cross-linked by diluting to a final spike concentration of 0.1 mg/ml  into room-temperature buffer 699 
containing 150 mM NaCl, 20 mM HEPES pH 7.4, 5% glycerol, and 7.5 mM glutaraldehyde. After 5 minutes cross-700 
linking, excess glutaraldehyde was quenched by adding sufficient 1 M Tris pH 7.4 stock to give a final 701 
concentration of 75 mM Tris and incubated for 5 minutes. For negative stain, carbon-coated grids (EMS, CF300-702 









grid for 10-15 s, blotted, and then stained with 2% uranyl formate. After air drying grids were imaged with a 704 
Philips EM420 electron microscope operated at 120 kV, at 82,000x magnification and images captured with a 2k x 705 
2k CCD camera at a pixel size of 4.02 Å.  706 
 707 
Image processing of negative stain images 708 
The RELION 3.0 program was used for all negative stain image processing. Images were imported, CTF-709 
corrected with CTFFIND, and particles were picked using a spike template from previous 2D class averages of 710 
spike alone. Extracted particle stacks were subjected to 2-3 rounds of 2D class averaging and selection to discard 711 
junk particles and background picks. Cleaned particle stacks were then subjected to 3D classification usi g a 712 
starting model created from a bare spike model, PDB 6vsb, low-pass filtered to 30 Å. Classes that showed clearly-713 
defined Fabs were selected for final refinements followed by automatic filtering and B-factor sharpening with the 714 
default Relion post-processing parameters. 715 
 716 
Cryo-EM sample preparation, data collection and processing 717 
To prepare Ab-bound complexes of the SARS-CoV-2 2P spike, the spike at a final concentration of 1–2 718 
mg/mL, in a buffer containing 2 mM Tris pH 8.0, 200 mM NaCl and 0.02% NaN3, was incubated with 5-6 fold 719 
molar excess of the Ab Fab fragments for 30–60 min.0.5% final concentration of glycerol was added to the sample 720 
right before freezing. 2.5 µL of protein was deposited on a Quantifoil-1.2/1.3 holey carbon grid that d been glow 721 
discharged in a PELCO easiGlow™ Glow Discharge Cleaning System for 15s at 15 mA. After a 30 s incubation 722 
in >95% humidity and 22 ºC, excess protein was blotted away for 2.5 seconds using a Whatman #1 filter paper 723 
before being plunge frozen into liquid ethane using a Leica EM GP2 plunge freezer (Leica Microsystems). Cryo-724 
EM data were collected on a Titan Krios (Thermo Fisher) equipped with a K3 detector (Gatan). Data were acquired 725 
using the Leginon system (Suloway et al., 2005). All the datasets were energy filtered through a either a 20eV or 726 
30eV slit. The dose was fractionated over 50 raw frames and collected at 50ms framerate. Individual frames were 727 
aligned and dose-weighted (Zheng et al., 2017). CTFestimation, particle picking and all downstream data 728 
processing steps were carried out in cryoSparc (Punjani et al., 2017). After two rounds of 2D classifications during 729 
which junk particles were discarded, heterogeneous refinement was performed using low pass filtered maps of 730 









heterogeneous refinement, followed by non-uniform refinement to obtain the final reconstructions that were used 732 
for model fitting.  733 
 734 
Cryo-EM structure fitting and analysis 735 
Previously published SARS-CoV-2 ectodomain structures of the all ‘down’ state (PDB ID 6VXX) and single 736 
RBD ‘up’ state (PDB ID 6VYB), and models of 2-RBD-up and 3-RBD-up states derived from these, were usedto 737 
fit the cryo-EM maps in Chimera (Pettersen et al., 2004). Models of Fabs were generated in SWIS-MODEL and738 
docked into the cryo-EM reconstructions using Chimera. Mutations were made in Coot (Emsley and Cowtan, 2004). 739 
Coordinates were fit to the maps using ISOLDE (Croll, 2018) followed by iterative refinement using Phenix 740 
(Afonine et al., 2018) real space refinement and subsequent manual coordinate fitting in Coot as needed. Structure 741 
and map analysis were performed using PyMol (Schrodinger, 2015), Chimera (Pettersen et al., 2004) and 742 
ChimeraX (Goddard et al., 2018). 743 
 744 
Live SARS-CoV-2 neutralization assays 745 
The SARS-CoV-2 virus (Isolate USA-WA1/2020, NR-52281) was deposited by the Centers for Disease 746 
Control and Prevention and obtained through BEI Resources, NIAID, NIH. SARS-CoV-2 Micro-neutralization 747 
(MN) assays were adapted from a previous study (Berry et al., 2004). In short, sera or purified Abs are diluted two-748 
fold and incubated with 100 TCID50 virus for 1 hour. These dilutions are used as the input material for a TCID50. 749 
Each batch of MN includes a known neutralizing contr l Ab (Clone D001; SINO, CAT# 40150-D001). Data are 750 
reported as the last concentration at which a test sample protects Vero E6 cells.  751 
SARS-CoV-2 Plaque Reduction Neutralization Test (PRNT) were performed in the Duke Regional 752 
Biocontainment Laboratory BSL3 (Durham, NC) as previously described with virus-specific modifications (Berry 753 
et al., 2004). Briefly, two-fold dilutions of a test sample (e.g. serum, plasma, purified Ab) were incubated with 50 754 
PFU SARS-CoV-2 virus (Isolate USA-WA1/2020, NR-52281) for 1 hour. The Ab/virus mixture is used to 755 
inoculate Vero E6 cells in a standard plaque assay (Coleman and Frieman, 2015; Kint et al., 2015). Briefly, 756 
infected cultures are incubated at 37°C, 5% CO2 for 1 hour. At the end of the incubation, 1 mL of a viscous 757 
overlay (1:1 2X DMEM and 1.2% methylcellulose) is added to each well. Plates are incubated for 4 days. After 758 









reported as the concentration at which 50% of input vir s is neutralized. A known neutralizing control Ab is 760 
included in each batch run (Clone D001; SINO, CAT# 40150-D001). GraphPad Prism was used to determine 761 
IC/EC50 values. 762 
SARS-CoV-2 nano-luciferase (nanoLuc), SARS-CoV nanoLuc and WIV1-CoV nanoLuc replication-763 
competent virus neutralization assay were described pr viously (Hou et al., 2020; Menachery et al., 2016; Sheahan 764 
et al., 2017).  765 
 766 
Pseudo-typed SARS-CoV-2 neutralization assay and infection-enhancing assays 767 
Neutralization of SARS-CoV-2 Spike-pseudotyped virus was performed by adopting an infection assay 768 
described previously (Korber et al., 2020) with lentiviral vectors and infection in either 293T/ACE2.MF (the cell 769 
line was kindly provided by Drs. Mike Farzan and Huihui Mu at Scripps). Cells were maintained in DMEM 770 
containing 10% FBS and 50 µg/ml gentamicin. An exprssion plasmid encoding codon-optimized full-length spike 771 
of the Wuhan-1 strain (VRC7480), was provided by Drs. Barney Graham and Kizzmekia Corbett at the Vaccine 772 
Research Center, National Institutes of Health (USA). The D614G mutation was introduced into VRC7480 by site-773 
directed mutagenesis using the QuikChange Lightning S te-Directed Mutagenesis Kit from Agilent Technologies 774 
(Catalog # 210518). The mutation was confirmed by full-length spike gene sequencing. Pseudovirions were 775 
produced in HEK 293T/17 cells (ATCC cat. no. CRL-11268) by transfection using Fugene 6 (Promega, Catalog 776 
#E2692). Pseudovirions for 293T/ACE2 infection were p oduced by co-transfection with a lentiviral backbone 777 
(pCMV ∆R8.2) and firefly luciferase reporter gene (pHR' CMV Luc) (Naldini et al., 1996). Culture supernatants 778 
from transfections were clarified of cells by low-speed centrifugation and filtration (0.45 µm filter) and stored in 1 779 
ml aliquots at -80 °C.  780 
For 293T/ACE2 neutralization assays, a pre-titrated dose of virus was incubated with 8 serial 3-fold or 5-fold 781 
dilutions of mAbs in duplicate in a total volume of 150 µl for 1 hr at 37 °C in 96-well flat-bottom poly-L-lysine-782 
coated culture plates (Corning Biocoat). Cells were suspended using TrypLE express enzyme solution (Thermo 783 
Fisher Scientific) and immediately added to all wells (10,000 cells in 100 µL of growth medium per well). One set 784 
of 8 control wells received cells + virus (virus control) and another set of 8 wells received cells only (background 785 









buffer was added to all wells. After a 10-minute incubation at room temperature, 100 µl of Bright-Glo luciferase 787 
reagent was added to all wells. After 1-2 minutes, 110 µl of the cell lysate was transferred to a black/white plate 788 
(Perkin-Elmer). Luminescence was measured using a PerkinElmer Life Sciences, Model Victor2 luminometer. 789 
Neutralization titers are the mAb concentration (IC50/IC80) at which relative luminescence units (RLU) were 790 
reduced by 50% and 80% compared to virus control wells after subtraction of background RLUs. Negative 791 
neutralization values are indicative of infection-enhancement. Maximum percent inhibition (MPI) is thereduction 792 
in RLU at the highest mAb concentration tested. 793 
For the TZM-bl neutralization assays, a pre-titrated dose of virus was incubated with serial 3-fold dilutions of 794 
test sample in duplicate in a total volume of 150 ul for 1 hr at 37 °C in 96-well flat-bottom culture plates. Freshly 795 
trypsinized cells (10,000 cells in 100 µl of growth medium containing 75  µg/ml DEAE dextran) were added to 796 
each well. One set of control wells received cells + virus (virus control) and another set received cells only 797 
(background control). After 68-72 hours of incubation, 150 µl of cultured medium was removed from each well, 798 
and 100ul of Britelite Luminescence Reporter Gene Assay System (PerkinElmer Life Sciences) were added and 799 
plates incubated for 2 min at room temperature. After this period 150 µl of the lysate was transferred to black solid 800 
plates (Costar) for measurements of luminescence in a Perking Elmer instrument. Neutralization titers a e the 801 
serum dilution at which relative luminescence units (RLU) were reduced by 50% and 80% compared to virus 802 
control wells after subtraction of background RLUs. MPI is the reduction in RLU at the highest mAb cone tration 803 
tested. Infection-enhancing assays were performed with the same format but using TZM-bl cell lines stably 804 
expressing each of the four human FcγR receptors (Perez et al., 2009). In this assay an increase in RLUs over the 805 
virus control signal represents FcR-mediated entry. 806 
 807 
Non-human primate protection study 808 
Groups of five cynomolgus macaques (2-4 kg) were giv n ntravenous infusion with Abs at 10 mg/kg body 809 
weight on Day -3, relative to infectious virus challenge. For each animal, 105 PFU (~106 TCID50) SARS-CoV-2 810 
virus (Isolate USA-WA1/2020) were diluted in 4 mL, and were given by 1 mL intranasally and 3 mL 811 
intratracheally on Day 0. Plasma and serum samples were collected on Day -5, 0, 2, and 4. Nasal swabs, na al 812 










Histopathology and Immunohistochemistry (IHC) 815 
Lung specimen from nonhuman primates were fixed in 10% neutral buffered formalin, processed, and blocked 816 
in paraffin for histological analysis. All samples were sectioned at 5 µm and stained with hematoxylin-eosin (H&E) 817 
for routine histopathology. Sections were examined un er light microscopy using an Olympus BX51 microsope 818 
and photographs were taken using an Olympus DP73 camera.  819 
 820 
Staining for SARS-CoV-2 antigen was achieved on the Bond RX automated system with the Polymer Define 821 
Detection System (Leica) used per manufacturer’s protocol. Tissue sections were dewaxed with Bond Dewaxing 822 
Solution (Leica) at 72℃ for 30 min then subsequently rehydrated with graded alcohol washes and 1x Immuno 823 
Wash (StatLab). Heat-induced epitope retrieval (HIER) was performed using Epitope Retrieval Solution 1 (Leica), 824 
heated to 100oC for 20 minutes. A peroxide block (Leica) was applied for 5 min to quench endogenous peroxidase 825 
activity prior to applying the SARS-CoV-2 Ab (1:2000, GeneTex, GTX135357). Abs were diluted in Background 826 
Reducing Ab Diluent (Agilent). The tissue was subsequently incubated with an anti-rabbit HRP polymer (Leica) 827 
and colorized with 3,3’-Diaminobenzidine (DAB) chrom gen for 10 min. Slides were counterstained with 828 
hematoxylin. For macrophage staining, Abs for the following markers were used: CD3 (T cell marker; BioRad, 829 
Catalog # MCA1477; 1:600 dilution), Iba1 (macrophage marker; Wako, Catalog # 019-19741; 1:800 dilution), 830 
CD68 (M1 macrophage marker, Sigma-Millipore, Catalog # HPA048982; 1:1000 dilution), CD163 (M2 831 
macrophage marker; Abcam, Catalog # ab182422; 1:500 dilution), HLA-DP/DQ/DR (Catalog # M1 macrophage 832 
marker; Dako, Catalog # M0775; 1:100 dilution), CD11b (monocyte/granulocyte marker; Abcam, Catalog # 833 
ab52478; 1:1000 dilution). 834 
Samples were evaluated by a board-certified veterinary pathologist in a blinded manner. Sections of the left 835 
caudal (Lc), right middle (Rm), and right caudal (Rc) lung were evaluated and scored for the presence of 836 
inflammation by H&E staining, and for the presence of SARS-CoV-2 nucleocapsid by IHC staining. The sum of 837 
Lc, Rm, and Rc scores in each animal shown in figures. 838 
 839 









For cytokine profiling, 7-fold concentrated cynomolgus macaques BAL samples were measured using a 25-841 
analyte multiplex bead array (Millipore, catalog # PRCYT2MAG40K) including sCD137, Eotaxin, sFasL, FGF-2, 842 
Fractalkine, Granzyme A, Granzyme B, IL-1α, IL-2, IL-4, IL-6, IL-16, IL-17A, IL-17E/IL-25, IL-21, IL-22, IL-23, 843 
IL-28A, IL-31, IL-33, IP-10, MIP-3α, Perforin, RANTES, TNFβ. Samples were prepared according to the 844 
manufacturer’s recommended protocol and read using a Flexmap 3D suspension array reader (Luminex Corp.). 845 
Data were analyzed using Bio-Plex manager software v6.2 (Bio-Rad). 846 
For human Ab quantification, SARS-CoV-2 Spike-2P protein, A/Solomon Islands/3/2006 hemagglutinin (HA) 847 
protein or bovine serum albumen (Sigma) was carbodiimi e coupled to MagPlex-C beads (Luminex Corp) 848 
according to the bead manufacturer’s protocol. Briefly, beads were washed in H2O then activated by incubation 849 
with 5 mg/mL sulfo-N-hydroxysulfosuccinimide and 5 mg/mL 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 850 
hydrochloride (ThermoFisher) for 20 minutes. Activaed beads were washed twice in PBS (ThermoFisher) and then 851 
vortexed at 1,500 RPM for two hours at room temperature with 25 µg protein per 5.0 x 106 beads. Labelled beads 852 
were washed in PBS (ThermoFisher), 1% BSA, 0.02% Tween-20, 0.05% Sodium Azide (all Sigma), counted using 853 
a hemacytometer and stored at -80°C. NHP sera were diluted 1:200 in assay buffer (PBS, 1% BSA, pH 7.4, Gibco), 854 
then 50 µL of diluted sera or monoclonal Ab 3-fold serially diluted in assay buffer (1000-0.45ng/mL) was added to 855 
a 96-well plate and mixed with 50 µL assay buffer containing 2500 BSA-conjugated beads (negative control) plus 856 
2500 HA or Spike-conjugated beads. The plate was shken at 800RPM for 60 minutes at room temperature, 857 
washed twice in assay buffer and then 100 µL 4 µg/mL biotin-conjugated mouse anti-human IgG Fc clone H2 858 
(Southern Biotech) in assay buffer was added to every w ll. The plate was shaken at 800 RPM for 30 minutes at 859 
room temperature, washed two times in assay buffer and then 50 µL 4 µg/mL streptavidin-r-phycoerythrin 860 
(Invitrogen) in assay buffer was added to every well. The plate was shaken at 800 RPM for 30 minutes at room 861 
temperature and washed twice in assay buffer. Beads were resuspended in 150 µL/well assay buffer, shaken at 800 862 
RPM for 15 minutes at room temperature and then analyzed on a BioPlex 200 bead reader (Bio-Rad). Sera antigen-863 
specific Ab concentrations were calculated using Bio-Plex Manager software (Bio-Rad) by extrapolating from the 864 
results of the serially-diluted monoclonal Ab. Sera with Abs above the upper limit of quantitation were re-assayed 865 
at 1:1000 or 1:5000. The limit of detection (LOD) for this assay is 0.278 µg/mL. 866 
 867 









Eleven to twelve-month old female immunocompetent BAL /c mice purchased from Envigo (BALB/c 869 
AnNHsd, stock# 047) were used for SARS-CoV-2 in vivo protection experiments as described previously (Dinnon 870 
et al., 2020). Ten-week-old HFH4-hACE2 transgenic mice were bred and maintained at the University of North 871 
Carolina at Chapel Hill and used for WIV-1 in vivo protection experiments. Mice were housed in groups of five 872 
animals per cage and fed standard chow diet. Virus inoculations were performed under anesthesia (Ketamine and 873 
Xylazine) and effort was taken to minimize animal suffering. For evaluating the prophylactic efficacy of mAbs, 874 
mice were intraperitoneally treated with 300 µg of each mAb or 150 µg of each mAb in combination 12 hours prior 875 
to infection. Mice were infected intranasally with 1X105 PFU of mouse-adapted SARS-CoV-2 2AA MA (Dinnon 876 
et al., 2020) or WIV-1. For evaluating the therapeutic efficacy of mAbs, mice were intraperitoneally treated with 877 
300 µg of each mAb or 150 µg of each mAb in combination 12 hours following infection. Forty-eight hours post 878 
infection, mice were sacrificed, and lungs were harvested for viral titer as measured by plaque assays and RNA 879 
analysis. In another study, fifty-two weeks old female BALB/c mice were i.p. injected with DH1052 (200ug/mice, 880 
n=10) or CH65 control Ab (200ug/mice, n=9). After 12 hours, mice were challenged with 1X10^4 PFU of mouse-881 
adapted SARS-CoV-2 MA10 virus (Leist et al., 2020a). Mice were sacrificed at day 4 post infection, andlungs 882 
were harvested for viral titer as measured by plaque assays and RNA analysis. The study was carried out in 883 
accordance with the recommendations for care and use of animals by the Office of Laboratory Animal Welfare 884 
(OLAW), National Institutes of Health and the Institu onal Animal Care. All mouse studies were performed at the 885 
University of North Carolina (Animal Welfare Assurance #A3410-01) using protocols (19-168) approved by the 886 
UNC Institutional Animal Care and Use Committee (IACUC) and all mouse studies were performed in a BSL3 887 
facility at UNC. 888 
 889 
Viral RNA Extraction and Quantification 890 
The assay for SARS-CoV-2 quantitative Polymerase Chain Reaction (qPCR) detects total RNA using the 891 
WHO primer/probe set E_Sarbeco (Charité/Berlin). A QI symphony SP (Qiagen, Hilden, Germany) automated 892 
sample preparation platform along with a virus/pathogen DSP midi kit and the complex800 protocol were used to 893 
extract viral RNA from 800 µL of pooled samples. A reverse primer specific to the envelope gene of SAR-CoV-2 894 









into cDNA using SuperScriptTM III Reverse Transcriptase (Thermo Fisher Scientific, Waltham, MA) along with 896 
RNAse Out (Thermo Fisher Scientific, Waltham, MA). The resulting cDNA was treated with RNase H (Thermo 897 
Fisher Scientific, Waltham, MA) and then added to acustom 4x TaqManTM Gene Expression Master Mix (Thermo 898 
Fisher Scientific, Waltham, MA) containing primers and a fluorescently labeled hydrolysis probe specific for the 899 
envelope gene of SARS-CoV-2 (forward primer 5’-ACA GGT ACG TTA ATA GTT AAT AGC GT-3’, reverse 900 
primer 5’-ATA TTG CAG CAG TAC GCA CAC A-3’, probe 5’-6FAM/AC ACT AGC C/ZENA TCC TTA CTG 901 
CGC TTC G/IABkFQ-3’). The qPCR was carried out on a QuantStudio 3 Real-Time PCR System (Thermo Fisher 902 
Scientific, Waltham, MA) using the following thermal cycler parameters: heat to 50°C, hold for 2 min, heat to 903 
95°C, hold for 10 min, then the following parameters a e repeated for 50 cycles: heat to 95°C, hold for 15 seconds, 904 
cool to 60°C and hold for 1 minute. SARS-CoV-2 RNA copies per reaction were interpolated using quantifica on 905 
cycle data and a serial dilution of a highly characterized custom DNA plasmid containing the SARS-CoV-2 906 
envelope gene sequence. Mean RNA copies per milliliter were then calculated by applying the assay dilution factor 907 
(DF=11.7). The limit of detection (LOD) for this assay is approximately 62 RNA copies per milliliter of sample. 908 
 909 
Subgenomic mRNA assay 910 
SARS-CoV-2 E gene and N gene subgenomic mRNA (sgRNA) was measured by a one-step RT-qPCR 911 
adapted from previously described methods (Wolfel et al., 2020; Yu et al., 2020). To generate standard cu ves, a 912 
SARS-CoV-2 E gene sgRNA sequence, including the 5’UTR leader sequence, transcriptional regulatory sequence 913 
(TRS), and the first 228 bp of E gene, was cloned ito a pcDNA3.1 plasmid. For generating SARS-CoV-2 N gene 914 
sgRNA, the E gene was replaced with the first 227 bp of N gene. The respectively pcDNA3.1 plasmids were 915 
linearized, transcribed using MEGAscript T7 Transcription Kit (ThermoFisher, Catalog # AM1334), and purified 916 
with MEGAclear Transcription Clean-Up Kit (ThermoFisher, Catalog # AM1908). The purified RNA products 917 
were quantified on Nanodrop, serial diluted, and aliquoted as E sgRNA or N sgRNA standards. 918 
RNA extracted from animal samples or standards were then measured in Taqman custom gene expression 919 
assays (ThermoFisher Scientific). For these assays we used TaqMan Fast Virus 1-Step Master Mix (ThermoFisher, 920 
catalog # 4444432) and custom primers/probes targeting the E gene sgRNA (forward primer: 5’ 921 
CGATCTCTTGTAGATCTGTTCTCE 3’; reverse primer: 5’ ATATTGCAGCAGT ACGCACACA 3’; probe: 5’ 922 









CGATCTCTTGTAGATCTGTTCTC 3’; reverse primer: 5’ GGTGAA CCAAGACGCAGTAT 3’; probe: 5’ FAM-924 
TAACCAGAATGGAGAACGCAGTG GG-BHQ1 3’). RT-qPCR reactions were carried out on a QuantStudio 3 925 
Real-Time PCR System (Applied Biosystems) or a StepOnePlus Real-Time PCR System (Applied Biosystems) 926 
using a program below: reverse transcription at 50°C for 5 minutes, initial denaturation at 95°C for 20 seconds, 927 
then 40 cycles of denaturation-annealing-extension at 95°C for 15 seconds and 60°C for 30 seconds. Standard 928 
curves were used to calculate E or N sgRNA in copies er ml; the limit of detections (LOD) for both E and N 929 
sgRNA assays were 12.5 copies per reaction or 150 copies per mL of BAL/nasal swab/nasal wash. 930 
 931 
QUANTIFICATION AND STATISTICAL ANALYSIS  932 
Data were plotted using Prism GraphPad 8.0. Wilcoxon rank sum exact test was performed to compare 933 
differences between groups with p-value < 0.05 considered significant using SAS 9.4 (SAS Institute, Cary, NC). 934 
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Supplementary Figure Legends 1210 
Figure S1. Isolation of SARS-CoV-2-reactive Abs from single cell-sorted plasmablasts and memory B cells of 1211 
SARS-CoV-2 and SARS-CoV-1 convalescent donors. Related to Figure 1. 1212 
(A) Symptom severity scores of the COVID-19 convalescent donor. The method to determine severity score is in 1213 
supplementary online material. Red arrows indicate the blood sampling time points that we used to isolate Abs. 1214 
(B) Viral load from nasopharyngeal (NP) swabs.  1215 
(C) Serum micro-neutralization titer. Micro-Neutraliz tion titers were defined as the highest serum dilution that 1216 
neutralize all the virus, or 99% inhibitory concentration (IC99). 1217 
(D) Flow cytometry gating strategy for unbiased plasm blasts sorting or antigen specific-memory B cells sorting. 1218 
At day 11 and day 15 post onset of COVID-19 symptom, plasmablasts (CD14-/CD16-/CD3-/CD235a-1219 
/CD19+/CD20low/IgD-/CD27high/CD38high) from a SARS-CoV-2 donor. Antigen specific B cells from SARS-CoV-1 1220 
and SARS-CoV-2 donors were sorted with different combinations of the SARS-CoV-2 S-2P, RBD, NTD probes. 1221 
Representative data for sorting Spike double positive, Spike+ or NTD+, as well as RBD+ or NTD+ subsets were 1222 
shown. 1223 
(E-H) Neutralization activity of RBD Abs. (E) Proporti n of SARS-CoV-2 RBD Abs (n=81) that exhibited 1224 
detectable neutralization in the microneutralization assay. (F) Neutralization IC50 and IC80 of RBD neutralizing Abs 1225 
(NAbs) against pseudotyped SARS-CoV-2. (G) Microneutralization titer, plaque reduction neutralization test 1226 
(PRNT) IC50 and IC80 of RBD NAbs against replication-competent SARS-CoV-2. Microneutralization titer was 1227 
defined as the lowest Ab concentration that neutralize all the virus, or 99% inhibitory concentration (IC99). Abs 1228 
with undetectable microneutralization titers are shown as gray symbols and nAbs are represented by blue symbols. 1229 
(H) RBD NAbs blocking of ACE2 binding to SARS-CoV-2 Spike (S) protein. Blocking titer is shown as IC50. 1230 
(I-J) Correlation analysis of RBD Abs between neutralization and ACE2 blocking activities. Spearman correlation 1231 
analysis were performed for (I) ACE2 blocking IC50 vs. PV neutralization IC50, as well as (J) for ACE2 blocking 1232 
IC50 vs. SARS-CoV-2 neutralization titers (indicated by the lowest concentration that shows no CPE). Purified 1233 
RBD Abs in Table S1 and S2 that have pseudovirus netralization data (n=59) or SARS-CoV-2 micro-1234 
neutralization assay data (n=80) were used in this analysis. P-value and r were indicated for each figures. 1235 
(K-M) Neutralization activity of NTD Abs. (K) Proportion of SARS-CoV-2 NTD Abs (n=41) that exhibited 1236 









against pseudotyped SARS-CoV-2. (M) Microneutralization titer, PRNT IC50 and IC80 of NTD neutralizing Abs 1238 
against replication-competent SARS-CoV-2. Abs with undetectable microneutralization titers are shown as gr y 1239 
symbols and neutralizing Abs are represented by orange symbols. Horizontal bars represent the geometric means 1240 
for each group of Abs. 1241 
 1242 
Figure S2. Binding and neutralization activities of down-selected SARS-CoV-2 Abs. Related to Figure 2. 1243 
(A-D) ELISA binding curves of down-selected Abs. Different SARS-CoV-2 or other CoV viral antigens were 1244 
coated on plates and detected with serial diluted (A) RBD infection-enhancing Abs, (B) RBD non-infection-1245 
enhancing Abs, (C) NTD infection-enhancing Abs, and(D) NTD non-infection-enhancing Abs. 1246 
(E-F) Neutralization curves for RBD Abs against pseudotyped (E) and replication-competent (F) SARS-CoV-2. 1247 
(G-H) Neutralization curves for NTD Abs against pseudotyped (G) and replication-competent (H) SARS-CoV-2. 1248 
(I-L) Neutralization curves for cross-neutralizing Abs against pseudotyped (I) and replication-competent (J) SARS-1249 
CoV-2, SARS-CoV-1 nanoluciferase (nLuc) virus (L), and Bat WIV1-CoV nLuc virus (L). 1250 
 1251 
 Figure S3. Comparison of RBD and NTD epitopes from NSEM. Related to Figure 2. 1252 
(A) A spike model (PDB 6ZGE) and corresponding Fab homology models were manually docked and rigidly fit 1253 
into each negative stain density map. 1254 
(B) The RBD of each model is enlarged and shown as a white surface, with the putative epitope of each Ab colored. 1255 
Black outline indicates the ACE2 binding footprint. 1256 
(C) Comparison to ACE2 footprint and epitopes of three published Abs with similar epitopes. See main text for 1257 
references. 1258 
(D) A spike model (PDB 6ZGE) and corresponding Fab homology models were manually docked and rigidly fit 1259 
into each negative stain density map. 1260 
(E) The NTD of each model is enlarged and shown as a white surface, with the epitope of each Ab colored. Orange 1261 
outline indicates the epitope of Ab 4A8, shown at bottom right. Outlines illustrate that the neutralizing Abs 1262 









(F) The model of spike complex with Fab 4A8 (orange ribbons, PDG 7C2L) is rigidly fit into each of the NSEM 1264 
maps (transparent surfaces). The close fit of 4A8 into DH1049, DH1050.1 and DH1050.2 indicate theses have the 1265 
same approach angle as 4A8, whereas DH1048 and DH1051 have slightly different approaches. 1266 
 1267 
Figure S4. In vitro analysis of human Abs and SARS-CoV-2 infected serum samples. Related to Figure 3, 1268 
Figure 5 and Figure 7. 1269 
(A-C) Effect of combining infection-enhancing RBD and NTD Abs on SARS-CoV-2 pseudovirus infection in 1270 
ACE2-expressing cells. The infection-enhancing NTD Ab DH1052 was tested alone (A) or mixed with infection-1271 
enhancing RBD Abs DH1041 (B) or DH1043 (C) in 1:13 ratio or 1:13250 ratio, respectively. The NTD:RBD Ab1272 
mixtures (orange), as well as RBD Ab alone (blue), were five-fold serially diluted and tested for neutralization 1273 
against SARS-CoV-2 D614G pseudovirus in 293T/ACE2 cells. 1274 
(D-F) Comparison of RBD and NTD directed serum Ab responses in SARS-CoV-2 infected humans.  1275 
(D) Serum IgG binding titers to RBD (blue) and NTD (salmon) as measured by ELISA as log area-under-curve 1276 
(AUC). Each symbol represents an individual study participant, with the mean binding titer for the visit day shown 1277 
as a black horizontal bar. 1278 
(E) Percent decrease in binding to NTD relative to RBD binding titer. Each symbol represents the change i  1279 
binding titer for an individual study subject. Mean decrease is shown as a black horizontal bar. 1280 
(F) Serum blocking of RBD neutralizing Ab DH1041 (blue) or NTD neutralizing Ab DH1050.1 (salmon), or non-1281 
neutralizing Ab DH1052 (burgundy) binding to SARS-CoV-2 spike. Black symbols show individual study 1282 
participants. Mean blocking percentage for the visit day is shown as a filled bar. 1283 
(G-H) Neutralization activities of neutralizing and enhancing Abs against mouse adapted SARS-CoV-2.  1284 
(G) NTD neutralizing Abs DH1050.1, RBD neutralizing and enhancing Abs DH1041 were tested for neutralization 1285 
activities against wild-type (WT) virus, mouse adapted 2AA MA virus, and mouse adapted MA10 virus in live 1286 
virus neutralization assay. CH65 Ab was used as a control. Mean value of neutralization (%) from duplicate wells 1287 
were shown. 1288 
(H) NTD enhancing Ab DH1052 and control Ab CH65 were tested for neutralization activities against wild-type 1289 
(WT) virus, mouse adapted 2AA MA virus, and mouse adapted MA10 virus in live virus neutralization assay. 1290 










Figure S5. Lung histopathology of Ab-treated and SARS-CoV-2 challenged cynomolgus macaques. Related 1293 
to Figure 5 and Figure 7. 1294 
(A) Representative images of hematoxylin and eosin (H&E) staining and SARS-CoV-2 antigen 1295 
immunohistochemistry (IHC) staining from each group. All images were taken at 10x magnification. The images in 1296 
this presentation are representative of the average sev rity of pathologic processes observed and record d during 1297 
microscopic evaluation. Red arrows indicate SARS-CoV-2 infection foci. 1298 
(B) Following microscopic evaluation of DH1052, 1 animal (BB536A) out of 5 animals in this group exhibited 1299 
histologic features that was substantially more sever  than the rest of the cohort and may suggest some degree of 1300 
Ab-mediated disease enhancement. The features were cha acterized by prominent perivascular mononuclear 1301 
inflammation (*) and a substantial amount of perivascular and alveolar edema (fluid; X). These findings suggest a 1302 
vaso-centric process with some degree of altered vascul r permeability. The remaining 4 animals in DH1052 group 1303 
had inflammatory changes that ranged from minimal to moderate severity and more infiltrates were mixed an  1304 
predominantly polymorphonuclear with lesser mononuclear cell involvement and present in the alveolar spaces. 1305 
(C-E) Expression of macrophage activation markers in macaque lung tissues. An animal from the CH65 control 1306 
group (C), the DH1052-treated animal (BB536A) that exhibited substantially more severe lung inflammation (D), 1307 
and an animal from the NTD NAb DH1050.1 group (E) were selected for Immunohistochemistry (IHC) staining. 1308 
Immunohistochemical staining was performed using MHCII, CD68, IBA1 and CD163 to detect classically 1309 
activated macrophages (M1) and/or alternatively activ ted macrophages (M2). CD11b is a macrophage/monocyte 1310 
marker and CD3 is a T cell marker. All images are 10x magnification; scale bars= 100µm. 1311 
 1312 
Figure S6. High dose NTD enhancing Ab DH1052 does not enhance SARS-CoV-2 replication or disease in 1313 
vivo. Related to Figure 5. 1314 
(A) Diagram of the macaque study design showing cynomolgus macaques (n=5 per group) were infused with hig  1315 
dose (30 mg/kg body weight) DH1052 or an irrelevant control CH65 Ab 3 days before 105 PFU of SARS-CoV-2 1316 
challenge via intranasal and intratracheal routes. Viral load including viral RNA and subgenomic RNA (sgRNA) 1317 
were measured at the indicated pre-challenge and post-challenge timepoints. Lungs were harvested on Day 4 post-1318 









(B-D) SARS-CoV-2 (B) E gene sgRNA, (C) N gene sgRNA and (D) E gene total viral RNA in bronchoalveolar 1320 
lavage (BAL) on Day 2 and Day 4 post challenge.  1321 
(E-G) SARS-CoV-2 (E) E gene sgRNA, (F) N gene sgRNA and (G) E gene total viral RNA in nasal swab on Day 2 1322 
and Day 4 post challenge. 1323 
(H-I) Lung inflammation. Sections of the left caudal (Lc), right middle (Rm), and right caudal (Rc) lung were 1324 
evaluated and scored for the presence of inflammation by hematoxylin and eosin (H&E) staining. (H) Summary of 1325 
inflammation scores. Symbols indicate the sums of Lc, Rm, and Rc scores in each animal. (I) Representative 1326 
images of lung H&E staining. 1327 
(J-K) Immunohistochemistry (IHC) staining for the presence of SARS-CoV-2 nucleocapsid in lungs. (J) Summary 1328 
of IHC scores. Symbols indicate the sums of Lc, Rm,and Rc scores in each animal. (K) Representative images of 1329 
lung IHC staining. Red arrows indicate SARS-CoV-2 infection foci. 1330 
LOD, limit of detection. Statistical significance in all the panels were determined using Wilcoxon rank sum exact 1331 
test. Asterisks show the statistical significance between indicated group and CH65 control group: ns, not significant, 1332 
*P<0.05, **P<0.01, ***P<0.001. 1333 
 1334 
Figure S7. Different doses of a cross-neutralizing Ab DH1047 treatments do not enhance SARS-CoV-2 1335 
replication in vivo. Related to Figure 7. 1336 
(A) Diagram of the macaque study design. Cynomolgus macaques (n=5 per group) were infused with DH1047 at 1337 
the dose of 10 mg/kg, 5 mg/kg, 1 mg/kg, 0.1 mg/kg weight. Macaques treated with 10 mg/kg weight of DH65 Ab 1338 
were set as the control group. Three days post-infusion, 105 PFU of SARS-CoV-2 challenge via intranasal and 1339 
intratracheal routes. Viral load including viral RNA and subgenomic RNA (sgRNA) were measured at the 1340 
indicated pre-challenge and post-challenge timepoints. Lungs were harvested on Day 4 post-challenge for 1341 
histopathology analysis. 1342 
(B) Serum human IgG concentrations at Day 2. 1343 
(C) Day 2 serum neutralization titers shown as the reciprocal serum dilution that inhibits 50% (ID50) of SARS-1344 
CoV-2 replication in Vero cells. 1345 
(D-E) SARS-CoV-2 (D) E gene sgRNA and (E) N gene sgRNA in bronchoalveolar lavage (BAL) on Day 2 and 1346 









(F-G) SARS-CoV-2 (F) E gene sgRNA and (G) N gene sgRNA in nasal swab on Day 2 and Day 4 post challenge. 1348 
(H-I) Lung inflammation. Sections of the left caudal (Lc), right middle (Rm), and right caudal (Rc) lung were 1349 
evaluated and scored for the presence of inflammation by hematoxylin and eosin (H&E) staining. (H) Summary of 1350 
inflammation scores. Symbols indicate the sums of Lc, Rm, and Rc scores in each animal. (I) Representative 1351 
images of lung H&E staining. 1352 
(J-K) Immunohistochemistry (IHC) staining for the presence of SARS-CoV-2 nucleocapsid in lungs. (J) Summary 1353 
of IHC scores. Symbols indicate the sums of Lc, Rm,and Rc scores in each animal. (K) Representative images of 1354 
lung IHC staining. Red arrows indicate SARS-CoV-2 infection foci. 1355 
LOD, limit of detection. Statistical significance in all the panels were determined using Wilcoxon rank sum exact 1356 
test. Asterisks show the statistical significance between indicated group and CH65 control group: ns, not significant, 1357 
*P<0.05, **P<0.01, ***P<0.001. 1358 
 1359 
 1360 
Supplementary Items (available online as excel sheet or PDF format) 1361 
 1362 
Table S1. High-throughput ELISA binding screen of Abs recovered from SARS-CoV-2 and SARS-CoV-1 1363 
donors. Related to Figure 1. 1364 
 1365 
Supplementary Table S2. Immunogenetic analysis of select neutralizing and non-neutralizing SARS-CoV-2 1366 
Abs. Related to Figure 2. 1367 
 1368 
Table S3. RBD and NTD Fabs affinity for Spike proteins. Related to Figure 2. 1369 
 1370 
Table S4. RBD and NTD Ab affinity for mouse CD16/FcγR3, CD16-2/FcγR4, CD32B/FcγR2b and 1371 
CD64/FcγR1. Related to Figure 5 and Figure 6. 1372 
 1373 
Table S5. Luminex cytokine profiling of BAL samples from cynomolgus macaques. Data set related to 1374 









challenge), Day 2 and Day 4 post-challenge were concentrated (x10) and measured using a 25-analyte multiplex 1376 
bead array by Luminex assay. The animal (BB536A) in DH1052 group that exhibited substantially more sever  1377 
disease and cytokine expression was marked in red. 1378 
 1379 










• RBD or NTD antibodies exhibited infection enhancement in vitro but not in vivo 
• Neutralizing or infection-enhancing NTD antibodies bound distinct epitopes 
• In vitro infection-enhancing antibodies protected from SARS-CoV-2 in vivo 
• Cross-reactive RBD neutralizing antibodies were protective--most potent, DH1047 
 
eTOC Blurb: 
Convalescent human-derived SARS-CoV-2 RBD and NTD antibodies mediated neutralization as well as 
infection-enhancement in vitro, yet infusion of these antibodies in mice or cynomolgus macaques 




















Days after COVID-19 symptoms onset
Years after SARS-CoV infection




RBD NTD S2 Spike only NP
SARS-CoV-2 donor Plasmablasts 773 101 11 4 42 1 43
SARS-CoV-2 donor Memory B cells 594 307 121 58 99 29 NA
SARS-CoV-1 donor Memory B cells 370 55 18 7 7 23 NA
Total 1737 463 150 69 148 53 43
Down-selected for production NA 187 81 41 65 0 0
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Pseudovirus in 293T/ACE2 cells














































































































































































































































































































































































































































































































































































































sgRNA E in nasal swab sgRNA N in nasal swab  
Day 2 Day 4 Day 2 Day 4
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sgRNA E in nasal swab sgRNA N in nasal swab  
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sgRNA E in BAL sgRNA N in BAL
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Voltage (kV) 300 300 300 300 300 
Electron dose (e-/Å2) 65.94 66.71 66.77 66.77 65.09 
Detector Gatan K3 Gatan K3 Gatan K3 Gatan K3 Gatan K3 
Pixel Size (Å) 1.058 1.058 1.058 1.058 1.058 
Defocus Range (µm) ~0.75-2.50 ~0.75-2.50 ~0.75-2.50 ~0.75-2.50 ~0.75-2.50 
Magnification 81000 81000 81000 81000 81000 
Micrographs 
collected 7362 9375 3440 1900 2154 
Reconstruction      
Software cryoSparc cryoSparc cryoSparc cryoSparc cryoSparc 
Particles 151,384 143,4115 127,401 133,814 426,025 
Symmetry C1 C1 C1 C1 C1 
Box size (pix) 350 350 350 350 350 
Resolution (Å) (FSC 0.143)* 3.42 2.97 3.4 3.66 3.35 
 
Refinement (Phenix)      
Protein residues 2994 4194 4251 3378 4296 
Chimera CC 0.72 0.77 0.79 0.68 0.73 
R.m.s. deviations      
Bond lengths (Å) 0.014 0.014 0.012 0.012 0.013 
Bond angles (°) 2.235 1.958 1.920 1.899 2.006 
Validation      
Molprobity score 1.99 1.25 1.41 1.17 1.53 
Clash score 2.19 0.40 0.15 0.23 0.42 
Favored rotamers (%) 96.62 98.41 97.65 98.88 97.48 
Ramachandran      
Favored regions (%) 88.15 92.97 89.16 90.03 89.05 
Allowed regions (%) 10.38 6.50 9.23 9.15 9.36 
Disallowed regions (%) 1.47 0.54 1.61 0.82 1.59 
EMRinger score 2.68 3.24 2.71 1.95 2.09 
 








2. Cryo-EM data processing details. (left) Representative micrograph, (middle) CTF fit and 
(right) Representative 2D class averages for (A) DH1041-Spike-2P (S2P) complex, (B) 
DH1043-S2P complex, (C) DH1047-S2P complex, (D) DH1050.1-S2P complex, (E) DH1052-
S2P complex.
2








3. Global and Local map resolutions for DH1041/S-2P complex. (A) Cryo-EM reconstruction of 
DH1041 bound to 1-RBD-up 2P spike. Top row show refined map and FSC curves. Bottom row shows 
refined colored by local resolution. Zoomed-in view of the S2 region is shown on the right with cryo-
EM map shown as blue mesh and underlying fitted model as sticks and colored by element (B) Cryo-
EM reconstruction of DH1041 bound to 2-RBD-up 2P spike. (C) Cryo-EM reconstruction of DH1041 
bound to 3-RBD-up 2P spike. 








4. Global and Local map resolutions for DH1043/S-2P complex. (A) Cryo-EM reconstructions of 
DH1043 bound to 1-RBD-up 2P spike Top two rows show refined maps, bottom row shows the FSC 
curve for each corresponding map. (B) Left. Refined cryo-EM map that was used for model building 
colored by local resolution. Right. Zoomed-in view of the S2 region with cryo-EM map shown as 
blue mesh and underlying fitted model as sticks and colored by element. (C) Zoomed-in view of the 
DH1043 interface with RBD. The cryo-EM map is shown as a blue mesh with underlying fitted 
model shown in cartoon representation, with the DH1047 HCDR1 loop colored yellow, HCDR2 
colored limon, HCDR3 cyan, and LCDR3 light blue.








5. Global and Local map resolutions for DH1047/S-2P complex. (A) Cryo-EM reconstructions of 
DH1047 bound to 3-RBD-up 2P spike. Top two rows show refined maps, bottom row shows the FSC 
curve for each corresponding map. (B) Left. Refined cryo-EM map that was used for model building 
colored by local resolution. Right. Zoomed-in view of the S2 region with cryo-EM map shown as blue 
mesh and underlying fitted model as sticks and colored by element. (C) Zoomed-in view of the 
DH1047 interface with RBD. The cryo-EM map is shown as a blue mesh with underlying fitted model 
shown in cartoon representation, with the DH1047 HCDR1 loop colored yellow,HCDR2 colored 
limon, HCDR3 cyan and LCDR1 orange.








6. Global and Local map resolutions for DH1050.1/S-2P complex. (A) Cryo-EM reconstruction of 
DH1050.1 bound to 3-RBD-down 2P spike. (B) Fourier shell correlation curves. (C) Left. Refined 
cryo-EM map colored by local resolution for the DH1050.1 bound to 3-RBD-down 2P spike. Right. 
Zoomed-in view of the S2 region with cryo-EM map shown as blue mesh and underlying fitted model 
as sticks and colored by element. (D) Cryo-EM reconstruction of DH1050.1 bound to 1-RBD-up 2P 
spike. (E) Fourier shell correlation curves. (F) Refined cryo-EM map colored by local resolution for 
the DH1050.1 bound to 1-RBD-up 2P spike. 6








7. Global and Local map resolutions for DH1052/S-2P complex. (A) Cryo-EM reconstruction of 
DH1052 bound to 3-RBD-down stabilized Spike “2P” (S-2P). (B) Fourier shell correlation curves. (C) 
Left. Refined cryo-EM map colored by local resolution for the DH1052 bound to 3-RBD-down S-2P. 
Right. Zoomed-in view of the S2 region with cryo-EM map shown as blue mesh and underlying fitted 
model as sticks and colored by element. (D) Cryo-EM reconstruction of DH1052 bound to 1-RBD-up S-
2P. (E) Fourier shell correlation curves. (F) Refined cryo-EM map colored by local resolution for the 
DH1052 bound to 1-RBD-up S-2P.
7
7. Global and Local map resolutions for DH1052/S-2P complex. 
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